fluorobenzenes has been researched along with Elevated Cholesterol in 255 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 152 (59.61) | 29.6817 |
| 2010's | 100 (39.22) | 24.3611 |
| 2020's | 3 (1.18) | 2.80 |
| Authors | Studies |
|---|---|
| Farooq Ur Rehman, RM; Khokhar, SA; Masood, S | 1 |
| Fujisawa, S; Fukatsu, Y; Sugimoto, Y | 1 |
| Alves Saldanha, S; Buclin, T; Cavassini, M; Courlet, P; Csajka, C; Decosterd, LA; Guidi, M; Marzolini, C; Stader, F; Stoeckle, M; Traytel, A | 1 |
| Daida, H; Hata, M; Kaku, K; Kawamori, R; Kishimoto, J; Kurabayashi, M; Masuda, I; Nohara, R; Sakuma, I; Yamazaki, T; Yokoi, H; Yoshida, M | 2 |
| Jialal, I; Sheely, D | 1 |
| Dormuth, CR; Ernst, P; Garg, AX; Hemmelgarn, BR; James, MT; Lafrance, JP; Levy, A; Paterson, JM; Raymond, CB; Teare, GF | 1 |
| Postmus, I; Trompet, S; Wouter Jukema, J | 1 |
| Kang, HC; Kim, CM; Kim, YS; Lee, JA; Lee, SY; Oh, HJ; Park, KC; Sin, DH; Sunwoo, S; Yang, YJ; Yu, BY | 1 |
| Choi, YH; DeGorter, MK; Dresser, GK; Hegele, RA; Iwuchukwu, O; Kim, RB; Myers, K; Schwarz, UI; Suskin, N; Tirona, RG; Wei, WQ; Wilke, RA; Zou, G | 1 |
| Camacho, X; Gomes, T; Grundy, S; Juurlink, DN; Mamdani, MM; Teng, JF | 1 |
| Arao, T; Hajime, M; Inokuchi, N; Kurozumi, A; Matsuoka, H; Mori, H; Narisawa, M; Okada, Y; Tanaka, K; Tanaka, Y; Torimoto, K; Yamamoto, S | 1 |
| Averna, M; Bays, HE; Brudi, P; De Pellegrin, A; Farnier, M; Giezek, H; Lee, R; Lowe, RS; Majul, C; Muller-Wieland, D; Triscari, J | 1 |
| Daida, H; Daimon, M; Hattori, N; Kuroki, T; Miyamoto, N; Miyauchi, K; Shimada, Y; Tanaka, R; Tanaka, Y; Ueno, Y; Urabe, T; Watanabe, M; Yamashiro, K | 1 |
| Elisaf, MS; Liberopoulos, EN; Milionis, HJ; Moutzouri, E; Tellis, CC; Tselepis, AD | 1 |
| Hu, M; Tomlinson, B | 2 |
| Aksoy, Y; Senen, K; Sivri, N; Tekin, G; Yalta, K; Yetkin, E | 1 |
| Ge, J; Wang, Z | 1 |
| Ballantyne, CM; Cain, VA; Hoogeveen, RC; Karlson, BW; Palmer, MK; Raya, JL | 1 |
| Hattori, H; Ishihara, M; Nagata, M; Takase, B; Tanaka, Y | 1 |
| Berger, H; Englert, H; Grittner, U; Katus, HA; Muckelbauer, R; Müller-Nordhorn, J; Prugger, C; Sonntag, F; Völler, H; Wegscheider, K; Willich, SN | 1 |
| Toth, PP | 1 |
| Hegele, RA; Joy, TR; Mahon, JL; McDonald, CG; Monjed, A; Zou, GY | 1 |
| Simonyi, G | 1 |
| Elisaf, MS; Kostapanos, MS; Rizos, CV | 1 |
| Athyros, VG; Giouleme, O; Karagiannis, A; Kargiotis, K; Katsiki, E; Katsiki, N; Mikhailidis, DP; Patsiaoura, K | 1 |
| Fialkow, J; Legg, JC; Nedergaard, BS; Nelson, P; Neutel, JM; Ramstad, D; Robinson, JG; Rogers, WJ; Scott, R; Somaratne, R; Wasserman, SM; Weiss, R | 1 |
| Ahn, T; Choi, IS; Han, SH; Koh, KK; Lee, K; Oh, PC; Seo, JG; Shin, EK; Suh, SY | 1 |
| Jinnouchi, H; Masuda, I; Matsui, K; Mori, H; Ogawa, H; Saito, Y; Sugawara, M; Sugiyama, S; Waki, M; Watada, H; Yoshiyama, M | 1 |
| Bays, HE; Colhoun, HM; Donahue, S; Du, Y; Hanotin, C; Jones, PH; Robinson, JG | 1 |
| Akinboro, O; Pomerantz, D; Williams, L | 1 |
| Joy, TR; Mahon, JL; Zou, GY | 1 |
| Huot, P; Huynh, NT | 1 |
| Ahn, CW; Cha, BS; Cho, Y; Choe, E; Choi, Y; Kang, ES; Lee, HC; Lee, YH; Seo, JW; Wang, HJ; Yun, Y | 1 |
| Cohen Tervaert, JW; de Jong, HJ; Helle, MJ; Klungel, OH; Meyboom, RH; Niskanen, L | 1 |
| Berdan, LG; Bessac, L; Bhatt, DL; Bittner, V; Diaz, R; Goodman, SG; Hanotin, C; Harrington, RA; Jukema, JW; Mahaffey, KW; Moryusef, A; Pordy, R; Roe, MT; Rorick, T; Sasiela, WJ; Schwartz, GG; Shirodaria, C; Steg, PG; Szarek, M; Tamby, JF; Tricoci, P; White, H; Zeiher, A | 1 |
| Ambegaonkar, BM; Polis, AB; Tershakovec, AM; Tipping, D; Tomassini, JE | 1 |
| Dubrovins'ka, TV; Skrypnyk, IM | 1 |
| Laufs, U | 1 |
| Funabiki, M; Hayashi, T; Iwaki, Y; Karita, M; Nakamura, Y; Tada, Y; Taguchi, S | 1 |
| Drapkina, OM; Korneeva, ON | 1 |
| Gadarla, M; Kearns, AK; Thompson, PD | 1 |
| Erdmann, E; Hoppe, UC | 1 |
| Kapur, NK; Musunuru, K | 1 |
| Dariolo, R; Noll, G; Riesen, WF | 1 |
| Bucci, A; Di Giacomo, S; Fraone, N; Mazza, F; Mazzarella, B; Stefanutti, C; Vivenzio, A | 1 |
| Beamer, B; Costa-Scharplatz, M; Frial, T; Gandhi, S; Ramanathan, K | 1 |
| Kastelein, JJ; Marck, R; Meuwese, MC; Mooij, HL; Nieuwdorp, M; Stroes, ES; van Lith, B; Vink, H | 1 |
| Nitta, K; Ogawa, T; Sawara, Y; Takei, T; Tsuchiya, K; Uchida, K; Yoshida, T | 1 |
| Avello L, M; Bravo D, M; Calvo M, C; Mennickent C, S | 1 |
| Bazzano, LA; Bucciarelli, T; D'Orazio, N; di Ilio, E; Mancini, B; Riccioni, G | 1 |
| Corretti, V; Ferrannini, E; Madec, S; Santini, E; Solini, A | 1 |
| D'iachkov, VA; Danilova, EA; Medvedeva, EA; Pikatova, EA; Seleznev, EI; Shchukin, IuV | 1 |
| Daubresse, JC; Herregods, MC; Lamotte, M; Michel, G; Vandenhoven, G; Vissers, E | 1 |
| Acikel, C; Dogru, T; Erdem, G; Genc, H; Ozgur, G; Ozgurtas, T; Sonmez, A; Tapan, S; Tasci, I | 1 |
| Calza, L; Chiodo, F; Colangeli, V; Manfredi, R; Pavoni, M; Pocaterra, D | 1 |
| Matsunaga, A; Miura, S; Nishikawa, H; Noda, K; Ogawa, M; Rainwater, DL; Saku, K; Shirai, K; Uehara, Y; Zhang, B | 1 |
| Arai, H; Daida, H; Hatsukami, TS; Hattori, N; Hirose, T; Ikeda, F; Kawamori, R; Maehara, T; Miyauchi, K; Ohishi, H; Sase, K; Suzuki, M; Takaya, N; Urabe, T; Yamamoto, M; Yoshida, K; Yuan, C | 1 |
| Kurabayashi, M; Yamazaki, T | 1 |
| Smith, M; Sullivan, D; Wlodarczyk, J | 1 |
| Jiang, GH; Qu, HY; Wang, ZY; Xiao, YW; Zhang, M; Zhang, Y | 1 |
| Ibrahim, W; Khan, FY | 1 |
| Glueck, CJ; Goldenberg, N; Khan, NA; Rawal, B; Wang, P; Yeramaneni, S | 1 |
| Bagaglia, F; Mannarino, E; Mannarino, MR; Pasqualini, L; Pirro, M; Razzi, R; Romagno, PF; Schillaci, G; Vaudo, G | 1 |
| Hattori, Y; Kasai, K; Kase, H; Okayasu, T; Satoh, H; Suzuki, K; Tomizawa, A | 1 |
| Englert, H; Katus, H; Meyer-Sabellek, W; Müller-Nordhorn, J; Sonntag, F; Völler, H; Wegscheider, K; Willich, SN; Windler, E | 1 |
| Basso, N; Berg, G; Buchholz, B; Carrión, CL; D'Annunzio, V; Donato, M; Erni, L; Gelpi, RJ; Miksztowicz, V; Schreier, L; Wikinski, R | 1 |
| Caputi, AP; Catania, MA; Giacci, L; Oteri, A; Polimeni, G; Russo, A; Salvo, F | 1 |
| Day, AG; Dulay, D; LaHaye, SA; Lahey, KA | 1 |
| Averna, M; Brudi, P; Farnier, M; Johnson-Levonas, AO; Massaad, R; Missault, L; Vandormael, K; Vaverkova, H; Viigimaa, M | 1 |
| Berneis, K; Kapur, NK; Rini, GB; Rizzo, M; Spinas, GA | 1 |
| Bots, ML; Crouse, JR; Dogan, S; Evans, GW; Grobbee, DE; O'Leary, DH; Palmer, MK; Plantinga, Y; Raichlen, JS | 1 |
| Keba, E; Laks, T; Leiner, M; Merilind, E; Otter, K; Petersen, M; Reinmets, S; Sööt, T; Väli, S | 1 |
| Coen, PM; Flynn, MG; Hannemann, RE; Markofski, MM; Pence, BD | 1 |
| Fabbri, G; Maggioni, AP | 1 |
| Bessias, N; Mikhailidis, DP; Paraskevas, KI; Perdikides, TP | 1 |
| Stewart, RA | 1 |
| Kang, BY; Mehta, JL; Palade, P; Sharma, SG; Wang, W | 1 |
| Lim, CH; Low, LP; Tan, AT; Tan, CE | 1 |
| Heintjes, EM; Herings, RM; Johansson, S; Penning-van Beest, FJ; Stalenhoef, AF | 1 |
| Kuriyama, G; Mori, Y; Tajima, N; Tanaka, T | 1 |
| Kanazawa, I; Sugimoto, T; Yamaguchi, T; Yamauchi, M | 1 |
| Bailey, KM; Balmforth, AJ; Hall, AS; Romaine, SP | 1 |
| Brandrup-Wognsen, G; Fox, KM; Gandhi, SK; Järbrink, K | 1 |
| Edwards, SJ; Gray, J; Lip, GY | 1 |
| D'Orazio, N; Mancini, B; Riccioni, G; Vitulano, N; Zanasi, A | 1 |
| Baum, L; Chu, TT; Hu, M; Ko, GT; Lee, VW; Li, EK; Lui, SS; Poon, EW; Tam, LS; Tomlinson, B | 1 |
| Chae, JK; Choi, JY; Hong, TJ; Jeong, MH; Kim, DS; Kim, KY; Kim, YJ; Kim, YN; Oh, SK; Park, JS; Seong, IW | 1 |
| Allgar, V; Chipperfield, R; Gaunt, R; Harvey, P; McCormack, T; Robinson, P | 1 |
| Carlson, DM; Gold, A; Jones, PH; Kelly, MT; McKenney, JM; Roth, EM; Setze, CM; Stolzenbach, JC; Williams, LA | 1 |
| Holford, TR; Kane, JP; Kocherla, M; Pullinger, CR; Ruaño, G; Seip, RL; Thompson, PD; Windemuth, A; Wu, AH | 1 |
| Averna, M; Brudi, P; Dong, Q; Farnier, M; Johnson-Levonas, AO; Missault, L; Shah, A; Vaverkova, H; Viigimaa, M | 2 |
| Abel, T; Fehér, J | 1 |
| MacDonald, GP | 1 |
| Averna, M; Brudi, P; Dong, Q; Farnier, M; Hanson, ME; Missault, L; Shah, A; Vaverkova, H; Viigimaa, M | 1 |
| Auteri, A; Ciabattoni, G; Ciani, F; Davì, G; Ferrante, E; Ghezzi, A; Lattanzio, S; Liani, R; Pasqui, AL; Puccetti, L; Santilli, F; Scarpini, F | 1 |
| Arranz Martínez, E; Gordillo López, FJ; Hermosa Hernán, JC; Ruiz García, A | 1 |
| Guo, F; He, YC; Huang, XH; Li, LJ; Sheng, YC; Wang, K; Xu, L; Yang, J; Zheng, QS | 1 |
| Ahmed, K; Ahn, Y; Cho, JG; Cho, SH; Choi, YH; Hachinohe, D; Hong, YJ; Hwang, SH; Jeong, MH; Kang, JC; Kim, JH; Kim, KH; Ko, JS; Lee, MG; Park, HW; Park, JC; Park, KH; Sim, DS; Yoon, HJ; Yoon, NS | 1 |
| Ason, B; Bartz, SR; Davis, HR; Dubinina, N; Flanagan, WM; Galinski, B; Hubbard, B; Kuklin, NA; Ranalletta, M; Sachs, AB; Soriano, F; Stefanni, A; Strack, A; Tadin-Strapps, M; Tep, S; Tetzloff, G; Wong, KK; Xu, Y; Zhu, L | 1 |
| Frick, M; Jaschke, W; Klug, G; Metzler, B; Pachinger, O; Schocke, MF; Zwick, RH | 1 |
| Al-Sarraf, A; Frohlich, J; Li, M; Sinclair, G | 1 |
| Aiello, VD; Casella Filho, A; Chagas, AC; da Luz, PL; Dourado, PM; Galvao, TF; Landim, MB; Mathias, W; Tsutsui, JM | 1 |
| Bovy, C; Grosch, S; Krzesinski, JM; Van Overmeire, L | 1 |
| Noda, K; Saku, K; Zhang, B | 2 |
| Ayaori, M; Ikewaki, K | 1 |
| Anzivino, C; Baldelli, E; Bertolotti, M; Carulli, L; Carulli, N; Corna, F; Del Puppo, M; Gabbi, C; Galli Kienle, M; Loria, P | 1 |
| Bays, HE; Davidson, MH; Flaim, D; Jones-Burton, C; Lowe, RS; Massaad, R; Tershakovec, AM | 1 |
| Cevik, C; Fish, RD; Izgi, C; Lyte, M; Meyerrose, G; Nugent, K; Otahbachi, M | 1 |
| Borges, NC; Fonseca, FA; Helfenstein, T; Izar, MC; Kasmas, SH; Moreira, FT; Moreno, RA; Ramos, SC; Rezende, VM; Silva, FC | 1 |
| Averna, M; Brudi, P; Dong, Q; Farnier, M; Johnson-Levonas, AO; Missault, L; Shah, A; Taggart, W; Vaverkova, H; Viigimaa, M | 1 |
| Demonte, A; Fassini, PG; Ferreira, ES; Neves, VA; Noda, RW; Silva, MA | 1 |
| Elisaf, M; Kei, AA; Kostapanos, MS; Liberopoulos, E; Mikhailidis, DP; Milionis, H; Moutzouri, E | 1 |
| Bucciarelli, T; Cipollone, F; D'Orazio, N; Mezzetti, A; Riccioni, G; Santovito, D; Scotti, L | 1 |
| Abdiche, Y; Bai, L; Chaparro-Riggers, J; Chin, SM; Dilley, J; Geng, T; Lee, NA; Liang, H; Lin, JC; Pons, J; Rajpal, A; Rossi, A; Shelton, DL; Strop, P; Sutton, JE; Tsai, D; Wu, S; Yu, J | 1 |
| de Almeida, EA; Ozaki, MR | 1 |
| Ishihara, M | 1 |
| Choi, H; Han, SH; Koh, KK; Lee, K; Quon, MJ; Sakuma, I; Shin, EK | 1 |
| Demonte, A; Ferreira, ES; Neves, VA; Silva, MA | 1 |
| Anzalone, D; Cain, VA; Cressman, MD; Shepherd, J; Stein, EA; Vidt, DG | 1 |
| Rosenhek, R | 1 |
| Choudhury, RP; Iacob, AO | 1 |
| Davies, GR | 1 |
| Ott, C; Schlaich, MP; Schmieder, RE; Schneider, MP | 1 |
| Hu, M; Li, EK; Lui, SS; Tam, LS; Tomlinson, B | 1 |
| Arca, M; Budal, S; Degli Esposti, E; Degli Esposti, L; Sangiorgi, D; Vigna, GB | 1 |
| Fehér, G; Szapáry, L | 1 |
| Al-Sarraf, A; Frohlich, J; Li, M | 1 |
| Flanagan, PV; Pais, A; Pretorius, CF; Tan, J | 1 |
| Bruckert, E; Dallongeville, J; Rosenbaum, D; Sabouret, P | 1 |
| Borges, NC; Figueiredo-Neto, AM; Fonseca, FA; França, CN; Helfenstein, T; Izar, MC; Kasmas, SH; Moreira, FT; Moreno, RA; Ramos, SC | 1 |
| Daida, H; Hirayama, A; Hiro, T; Matsuzaki, M; Saito, S; Takayama, T; Yamagishi, M; Yamaguchi, T | 1 |
| Elisaf, MS; Florentin, M; Kei, AA; Kostapanos, MS; Liamis, G; Liberopoulos, EN; Rizos, CV | 1 |
| Ballantyne, CM; Cain, VA; Loscalzo, J; Pitt, B; Raichlen, JS | 1 |
| Zateĭshchikov, DA | 1 |
| Masmiquel Comas, L; Nicolau Ramis, J; Rivera Irigoín, R; Terrasa Sagrista, F | 1 |
| Castiglioni, L; Cosentino, M; Dentali, F; Grandi, AM; Guasti, L; Legnaro, M; Maio, RC; Maresca, AM; Marino, F; Mongiardi, C; Rasini, E; Schembri, L | 1 |
| Ott, C; Raff, U; Schmieder, RE; Schneider, MP; Titze, SI | 1 |
| Brudi, P; Hanson, ME; Jimenez, JG; Massaad, R; McPeters, G; Pirags, V; Rosen, JB; Triscari, J; Vides, H | 1 |
| De Buyzere, ML; Delanghe, JR; Fiers, T; Speeckaert, MM; Wehlou, CM | 1 |
| Arakawa, K; Fujinami, T; Itakura, H; Mabuchi, H; Matsuzawa, Y; Oikawa, S; Sasaki, J; Takemura, K; Toyota, T; Tsushima, M; Yamada, N; Yamamoto, A | 1 |
| Carswell, CI; Jarvis, B; Plosker, GL | 1 |
| Bolego, C; Catapano, AL; Cignarella, A; Paoletti, R; Poli, A | 1 |
| Evans, M; Rees, A; Roberts, A | 1 |
| McTaggart, F; Olsson, AG; Raza, A | 1 |
| Bays, HE; Brown, WV; Chitra, R; Hassman, DR; Hutchinson, H; McKenney, J; Miller, E | 1 |
| Istad, H; Luurila, O; Olsson, AG; Ose, L; Pears, J; Southworth, H; Stender, S; Tuomilehto, J; Wiklund, O; Wilpshaar, JW | 1 |
| Ballantyne, CM; Chitra, RR; Knopp, RH; McPherson, R; Schneck, DW; Simonson, SG | 1 |
| Caslake, M; Chapman, MJ; McTaggart, F; Packard, C | 1 |
| Stein, EA | 1 |
| Blasetto, JW; Brown, WV; Chitra, R; Raza, A; Stein, EA | 1 |
| Barter, P; Hunninghake, DB; Hutchinson, HG; McKenney, JM; Shepherd, J | 1 |
| Caplan, RJ; Davidson, MH; Pears, JS; Rader, DJ | 1 |
| Berry, DA; Berry, SM; McKellar, J; Pearson, TA | 1 |
| Bays, HE; Blasetto, JW; Cain, VA; Davidson, MH; Jones, PH; McKenney, JM; Miller, E; Stein, EA | 1 |
| Kirkpatrick, P; Quirk, J; Thornton, M | 1 |
| Cheng, TO | 1 |
| Adamczyk, MA; Blasetto, JW; Bryzinski, BS; Cain, VA; Jones, PH; McKenney, JM | 1 |
| Blasetto, J; Caplan, R; Dane, A; Hutchison, H; Strutt, K | 1 |
| Edwards, JE; Moore, RA | 1 |
| Avogaro, A | 1 |
| Bernini, F; Catapano, AL | 1 |
| Baldasseroni, S; Fabbri, G; Maggioni, AP | 1 |
| Scheen, AJ | 1 |
| Dane, A; Goto, Y; Raza, A; Saito, Y; Strutt, K | 1 |
| Barter, PJ; Bonnet, J; Cheung, RC; Kallend, D; Morrell, JM; Raza, A; Schuster, H; Stender, S; Watkins, C | 1 |
| Mason, P | 1 |
| Desai, A; Gawde, A; Jain, MM; Jayaram, S; Naikawadi, AA | 1 |
| Bolognese, MA; Caplan, R; Cressman, M; Hutchinson, H; Raza, A; Schwartz, GG; Tremblay, BP | 1 |
| Chu, KM; Ding, YA; Leu, HB; Lu, TM; Sheu, WH; Yin, WH | 1 |
| Boutros, T; Cutler, DL; Kosoglou, T; Maxwell, SE; Statkevich, P; Suresh, R; Tiessen, R; Yang, B; Zhu, Y | 1 |
| Blasetto, JW; Kallend, D; Littlejohn, TW; Packard, C; Shepherd, J; Smith, K; Stein, EA; Walker, J | 1 |
| Dallongeville, J; Farnier, M; Ferrières, J; Lepen, C; Schuster, H | 1 |
| Blasetto, JW; Caplan, RJ; Ferdinand, KC; Gold, A; Hunninghake, DB; Jones, PH; Stein, EA | 1 |
| Katus, H; Meyer-Sabellek, W; Müller-Nordhorn, J; Sonntag, F; Völler, H; Wegscheider, K; Willich, SN; Windler, E | 1 |
| Feely, J; Sigurdsson, EL; Strandberg, TE | 1 |
| Ballantyne, CM; Chitra, R; Miller, E | 1 |
| Abbasi, F; Cain, V; Chu, JW; Hutchinson, H; Lamendola, C; Leary, E; McLaughlin, T; Reaven, G; Stein, E | 1 |
| Asagami, T; Lee, KH; Li, W; Matsushita, H; Tsao, PS | 1 |
| Hirsch, M; Jones, P; O'Donnell, JC | 1 |
| Cheung, RC; Kallend, D; Morrell, JM; Schuster, H; Watkins, C | 1 |
| Franken, AA; Vincent, HH; Wolffenbuttel, BH | 1 |
| Barter, P; Kallend, D; Schuster, H; Stender, S; Watkins, C | 1 |
| Brady, WE; Catapano, A; King, TR; Palmisano, J | 1 |
| Culhane, NS; Lettieri, SL; Skae, JR | 1 |
| Kallend, D; Leiter, LA; Tuomilehto, J | 1 |
| Cardona-Muñoz, EG; Fonseca, FA; Fuenmayor, N; Marotti, M; Ruiz, A; Silva, JM | 1 |
| Ferdinand, KC | 1 |
| Hirsch, M; O'donnell, J; Olsson, A | 1 |
| Blideskog, M; Dunselman, P; Eskilson, C; Hjalmarson, A; Kjekshus, J; McMurray, JV; Waagstein, F; Wedel, H; Wessman, P; Wikstrand, J | 1 |
| Juszczyk, MA; Seip, RL; Thompson, PD | 1 |
| Hirata, M; Izuishi, K; Matsunaga, K; Ohfuji, K; Shimada, H; Shinagawa, J; Smith, G; Yamaguchi, M; Yano, S | 1 |
| Bots, AF; Kastelein, JJ | 1 |
| Mareev, VIu | 1 |
| Tiwari, A | 1 |
| Ahmed, MH | 1 |
| Ditmarsch, M; Harris, S; McTaggart, F; Sager, PT; Sorof, JM; Vidt, DG | 1 |
| Agloria, M; Aregawi, D; Glueck, CJ; Gogineni, S; Khalil, Q; Munjal, J; Wang, P; Winiarska, M | 1 |
| Knopp, RH; Paramsothy, P | 1 |
| Haffner, S; Lloret, R; Stein, M; Ycas, J | 1 |
| Guthrie, RM | 1 |
| Dhummauppakorn, R; Kitiyadisai, C; Sansanayudh, N; Wongwiwatthananukit, S | 1 |
| Daskalopoulou, SS; Mikhailidis, DP | 1 |
| Ballantyne, CM; Brady, WE; Catapano, AL; Davidson, MH; Gazzara, RA; Tershakovec, AM; Tomassini, JE | 1 |
| Mannarino, E; Mannarino, MR; Paltriccia, R; Pirro, M; Savarese, G; Schillaci, G; Siepi, D; Vaudo, G | 1 |
| Mackie, BD; Miller, J; Nell, C; Satija, S; Sperling, LS | 1 |
| Leiter, LA; Miller, P; Palmer, M; Reckless, JP; Rosenson, RS; Schleman, M; Schulte, KL; Sosef, F; Stein, E | 1 |
| Ott, C; Schäufele, T; Schlaich, MP; Schmidt, BM; Schmieder, RE; Titze, SI | 1 |
| Ballantyne, CM; Duffield, E; Eber, B; Moccetti, T; Sosef, F; Vogt, A; Weiss, R | 1 |
| Asztalos, BF; Dallal, GE; Horvath, KV; Jones, PH; Le Maulf, F; McTaggart, F; Schaefer, EJ; Stein, E | 1 |
| Bellomo, A; Ettorre, E; Mancinella, M; Marigliano, V; Troisi, G | 1 |
| Davidson, M; Gandhi, SK; Kamat, SA | 1 |
| Deedwania, PC; Gold, A; Gupta, M; Stein, M; Ycas, J | 1 |
| Frial, T; Miller, PS; Tran, YB | 1 |
| Gao, RL | 1 |
| Bianchi, C; Canale, ML; Del Prato, S; Delle Donne, MG; Di Bello, V; Mariani, M; Miccoli, R; Nardi, C; Palagi, C; Penno, G; Talini, E | 1 |
| Bays, HE; Blasetto, JW; Fox, KM; Gandhi, SK; Ohsfeldt, RL | 1 |
| Backes, JM; Gibson, CA; Moriarty, PM; Ruisinger, JF | 1 |
| Barrett, PH; Hoang, A; Nestel, P; Ooi, E; Sviridov, D; Watts, G | 1 |
| Mascitelli, L; Pezzetta, F | 1 |
| Betteridge, DJ; Gibson, JM; Sager, PT | 1 |
| Amerena, J; Ballantyne, CM; Brice, E; Farnier, M; Gold, A; Guthrie, RM; Harats, D; Le Maulf, F; Ma, PT; Melezínková, H; Sager, P; Stein, EA | 1 |
| Blasetto, J; Gandhi, S; Harley, CR; Heien, H; Nelson, SP; Sasane, R | 1 |
| Bäumer, A; Burger, D; de Groot, E; Fätkenheuer, G; Koopmans, P; Kroon, F; Reiss, P; Rockstroh, J; Sankatsing, R; Schippers, E; Stroes, E; van der Lee, M; van der Ven, A; Vogel, M; Wyen, C | 1 |
| Davidson, MH; Fox, KM; Gandhi, SK; Ohsfeldt, RL | 1 |
| Blasetto, JW; Davidson, MH; Fox, KM; Gandhi, SK; Ohsfeldt, RL | 1 |
| Lee, YT; Ro, YM; Sim, KH; Sriratanasathavorn, C; Tomlinson, B; Zhu, JR | 1 |
| Carpi, A; Di Maria, C; Franzoni, F; Galetta, F; Rossi, M; Santoro, G | 1 |
| Cain, VA; Chu, B; Hamar, W; Hatsukami, TS; Kraiss, LW; Liu, F; Neradilek, B; Parker, DL; Polissar, NL; Raichlen, JS; Saam, T; Takaya, N; Underhill, HR; Waterton, JC; Yuan, C; Zhao, XQ | 1 |
| Crouse, JR | 1 |
| Chiang, CE; Huang, SS; Sung, SH | 1 |
| Stalenhoef, AF | 1 |
| Asmar, R; Duffield, E; Faergeman, O; Hill, L; Sosef, F; Wiklund, O; Windler, E | 1 |
| Gandhi, S; Harley, CR; Heien, H; Nelson, SP | 1 |
| Fox, KM; Gandhi, SK; McKenney, JM; Ohsfeldt, RL | 1 |
| Buckett, L; Davidson, R; Holdgate, G; McCormick, A; McTaggart, F; Schneck, D; Smith, G; Warwick, M | 1 |
| Olsson, AG | 2 |
| Brown, WV | 1 |
| McKellar, J; Mizan, J; Olsson, AG; Pears, J; Raza, A | 1 |
| Ho, C | 1 |
| Chitra, R; Davidson, M; Gotto, AM; Hutchinson, H; Ma, P; Raza, A; Stein, EA | 1 |
| Chong, PH; Yim, BT | 1 |
| Fahmy, M; Mahla, G; Mizan, J; Paoletti, R; Southworth, H | 1 |
| Chapman, MJ; McTaggart, F | 1 |
52 review(s) available for fluorobenzenes and Elevated Cholesterol
| Article | Year |
|---|---|
Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases.
Topics: Acute Kidney Injury; Adult; Aged; Atorvastatin; British Columbia; Cohort Studies; Confidence Intervals; Databases, Factual; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorobenzenes; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Incidence; Logistic Models; Male; Middle Aged; Odds Ratio; Patient Safety; Pyrimidines; Pyrroles; Retrospective Studies; Risk Assessment; Rosuvastatin Calcium; Simvastatin; Sulfonamides; United Kingdom; United States | 2013 |
Evaluation of the pharmacokinetics and drug interactions of the two recently developed statins, rosuvastatin and pitavastatin.
Topics: Animals; Cytochrome P-450 Enzyme System; Drug Evaluation, Preclinical; Drug Interactions; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Models, Animal; Pyrimidines; Quinolines; Rosuvastatin Calcium; Sulfonamides | 2014 |
Managing hypercholesterolemia and preventing cardiovascular events in elderly and younger Chinese adults: focus on rosuvastatin.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Asian People; Atherosclerosis; China; Coronary Disease; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipidemias; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Young Adult | 2014 |
An update on the benefits and risks of rosuvastatin therapy.
Topics: Atherosclerosis; Cardiovascular Diseases; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Primary Prevention; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2014 |
Benefit-risk assessment of rosuvastatin in the treatment of atherosclerosis and related diseases.
Topics: Atherosclerosis; Cholesterol, LDL; Drug-Related Side Effects and Adverse Reactions; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrimidines; Risk Assessment; Rosuvastatin Calcium; Sulfonamides | 2014 |
[Lipid lowering by rosuvastatin: how do statins differ?].
Topics: Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Dose-Response Relationship, Drug; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrimidines; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Sulfonamides; Survival Rate | 2015 |
[Cardiology 2008].
Topics: Anticholesteremic Agents; Antihypertensive Agents; Aortic Valve Stenosis; Cardiac Catheterization; Cardiovascular Diseases; Drug Therapy, Combination; Electrocardiography; Fluorobenzenes; Heart Failure; Heart Valve Prosthesis Implantation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Myocardial Infarction; Platelet Aggregation Inhibitors; Pyrimidines; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Sulfonamides | 2008 |
Clinical efficacy and safety of statins in managing cardiovascular risk.
Topics: Atherosclerosis; Cardiovascular Diseases; Chemical and Drug Induced Liver Injury; Cholesterol, LDL; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Kidney Diseases; Muscular Diseases; Pyrimidines; Risk Assessment; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2008 |
[Pleiotropic effects of statins].
Topics: Anticholesteremic Agents; Antioxidants; Atherosclerosis; Atorvastatin; Endothelium, Vascular; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Oxidative Stress; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2008 |
Comparison of benefits and risks of rosuvastatin versus atorvastatin from a meta-analysis of head-to-head randomized controlled trials.
Topics: Atorvastatin; Cholesterol, LDL; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Muscular Diseases; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Sulfonamides | 2008 |
Rosuvastatin induced rhabdomyolysis in a low risk patient: a case report and review of the literature.
Topics: Creatine Kinase; Creatinine; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Myoglobin; Myoglobinuria; Pyrimidines; Qatar; Rhabdomyolysis; Rosuvastatin Calcium; Sulfonamides | 2009 |
Quantitative and qualitative effects of rosuvastatin on LDL-cholesterol: what is the clinical significance?
Topics: Aged; Cardiovascular Diseases; Cholesterol, LDL; Clinical Trials as Topic; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Primary Prevention; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2009 |
Cardiovascular risk reduction: what do recent trials with rosuvastatin tell us?
Topics: Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Disease Progression; Evidence-Based Medicine; Fluorobenzenes; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Inflammation; Kidney Failure, Chronic; Practice Guidelines as Topic; Primary Prevention; Pyrimidines; Risk Factors; Risk Reduction Behavior; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2009 |
The influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapy.
Topics: Anticholesteremic Agents; Asian People; Atorvastatin; Fluorobenzenes; Gene Frequency; Haplotypes; HeLa Cells; Hepatocytes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Liver; Liver-Specific Organic Anion Transporter 1; Organic Anion Transporters; Pharmacogenetics; Polymorphism, Single Nucleotide; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2010 |
Effectiveness of rosuvastatin in reducing LDL-C and target LDL-C goal attainment in real-world clinical practice.
Topics: Cholesterol, LDL; Down-Regulation; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Population; Professional Practice; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2009 |
Comparison of sequential rosuvastatin doses in hypercholesterolaemia: a meta-analysis of randomised controlled trials.
Topics: Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoproteins; Male; MEDLINE; Pyrimidines; Randomized Controlled Trials as Topic; Risk Factors; Rosuvastatin Calcium; Sulfonamides | 2010 |
[Role of rosuvastatin in current lipid-lowering therapy].
Topics: Acute Coronary Syndrome; Atherosclerosis; C-Reactive Protein; Cholesterol; Disease Progression; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Meta-Analysis as Topic; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2010 |
Renal safety of intensive cholesterol-lowering treatment with rosuvastatin: a retrospective analysis of renal adverse events among 40,600 participants in the rosuvastatin clinical development program.
Topics: Aged; Aged, 80 and over; Biomarkers; Cholesterol, LDL; Clinical Trials as Topic; Evidence-Based Medicine; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Kidney; Male; Middle Aged; Proportional Hazards Models; Pyrimidines; Renal Insufficiency; Retrospective Studies; Risk Assessment; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Time Factors | 2012 |
[Almanac 2011: Valvular heart disease. Review of select studies that have driven recent advances in clinical cardiology: in the care of the Editors' Network Task Force of the European Society of Cardiology].
Topics: Age Factors; Almanacs as Topic; Aortic Valve Insufficiency; Aortic Valve Stenosis; Austria; Biomarkers; Biomedical Research; Cardiac Surgical Procedures; Cardiology; Endocarditis; Fluorobenzenes; Heart Valve Diseases; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Mitral Valve Insufficiency; Natriuretic Agents; Natriuretic Peptide, Brain; Periodicals as Topic; Prevalence; Prognosis; Pyrimidines; Randomized Controlled Trials as Topic; Risk Factors; Rosuvastatin Calcium; Severity of Illness Index; Smoking; Sulfonamides; Tricuspid Valve Insufficiency | 2012 |
Targeting HDL-cholesterol to reduce residual cardiovascular risk.
Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pravastatin; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Sulfonamides | 2012 |
[Features of the use of rosuvastatin in clinical practice].
Topics: Biological Availability; Cardiovascular Diseases; Comorbidity; Fluorobenzenes; Glomerular Filtration Rate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Insulin Resistance; Metabolic Clearance Rate; Pharmacogenetics; Pharmacovigilance; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Tissue Distribution; Treatment Outcome | 2012 |
Rosuvastatin.
Topics: Clinical Trials as Topic; Fluorobenzenes; Humans; Hypercholesterolemia; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2002 |
Novel statins: pharmacological and clinical results.
Topics: Animals; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Naphthalenes; Pyrimidines; Quinolines; Rosuvastatin Calcium; Sulfonamides | 2002 |
The future direction of cholesterol-lowering therapy.
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Clinical Trials as Topic; Drug Therapy, Combination; Ezetimibe; Fluorobenzenes; Forecasting; Humans; Hypercholesterolemia; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2002 |
Rosuvastatin: a highly effective new HMG-CoA reductase inhibitor.
Topics: Animals; Cholesterol; Clinical Trials as Topic; Dose-Response Relationship, Drug; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipoproteinemia Type II; Hypertriglyceridemia; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2002 |
New dimension of statin action on ApoB atherogenicity.
Topics: Animals; Apolipoproteins B; Cholesterol, LDL; Controlled Clinical Trials as Topic; Coronary Artery Disease; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Pyrimidines; Rosuvastatin Calcium; Sensitivity and Specificity; Sulfonamides; Treatment Outcome | 2003 |
Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Drug Administration Schedule; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Least-Squares Analysis; Male; Middle Aged; Multicenter Studies as Topic; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2003 |
Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Drug Administration Schedule; Europe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Multicenter Studies as Topic; Practice Guidelines as Topic; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Risk; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2003 |
Lipid and apolipoprotein ratios: association with coronary artery disease and effects of rosuvastatin compared with atorvastatin, pravastatin, and simvastatin.
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoproteins; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Europe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Least-Squares Analysis; Lipids; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2003 |
Comparison of the dose-response relationships of 2 lipid-lowering agents: a Bayesian meta-analysis.
Topics: Anticholesteremic Agents; Atorvastatin; Bayes Theorem; Cholesterol, LDL; Dose-Response Relationship, Drug; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2003 |
More Western hypercholesterolemic patients achieve Japan Atherosclerosis Society LDL-C goals with rosuvastatin therapy than with atorvastatin, pravastatin, or simvastatin therapy.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Drug Evaluation; Europe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Japan; Male; Middle Aged; Multicenter Studies as Topic; Pravastatin; Pyrimidines; Pyrroles; Racial Groups; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome; United States | 2004 |
Statins in hypercholesterolaemia: a dose-specific meta-analysis of lipid changes in randomised, double blind trials.
Topics: Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Female; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Male; Pravastatin; Pyridines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Triglycerides | 2003 |
[Diabetes and multimetabolic syndrome].
Topics: Diabetes Mellitus; Fluorobenzenes; Humans; Hypercholesterolemia; Hyperlipidemias; Insulin Resistance; Metabolic Syndrome; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2003 |
[Rosuvastatin: pharmacologic features].
Topics: Animals; Arteriosclerosis; Biotransformation; Cholesterol; Drug Interactions; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipidemias; Hypolipidemic Agents; Inflammation; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Triglycerides | 2003 |
[Ongoing trials and future prospects].
Topics: Cardiovascular Diseases; Clinical Trials as Topic; Fluorobenzenes; Forecasting; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Inflammation; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2003 |
[Drug of the month. Rosuvastatin (Crestor)].
Topics: Anticholesteremic Agents; Belgium; Cholesterol, HDL; Cholesterol, LDL; Dose-Response Relationship, Drug; Fluorobenzenes; Humans; Hypercholesterolemia; Morbidity; Patient Selection; Pyrimidines; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Triglycerides | 2004 |
[Hypercholesterolemia, practical guidelines].
Topics: Arteriosclerosis; C-Reactive Protein; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Practice Guidelines as Topic; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Sulfonamides | 2004 |
Lipid altering-efficacy of ezetimibe co-administered with simvastatin compared with rosuvastatin: a meta-analysis of pooled data from 14 clinical trials.
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Clinical Trials as Topic; Drug Therapy, Combination; Ezetimibe; Fluorobenzenes; Humans; Hypercholesterolemia; Pyrimidines; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2005 |
Rosuvastatin for the treatment of hypercholesterolemia.
Topics: Anticholesteremic Agents; Clinical Trials as Topic; Drug Interactions; Fluorobenzenes; Humans; Hypercholesterolemia; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2005 |
A review of the efficacy of rosuvastatin in patients with type 2 diabetes.
Topics: Anticholesteremic Agents; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipidemias; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2004 |
Rosuvastatin: a risk-benefit assessment for intensive lipid lowering.
Topics: Animals; Atherosclerosis; Cardiovascular Diseases; Cholesterol, LDL; Dose-Response Relationship, Drug; Drug Interactions; Drug Labeling; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Product Surveillance, Postmarketing; Pyrimidines; Randomized Controlled Trials as Topic; Rhabdomyolysis; Risk Assessment; Rosuvastatin Calcium; Sulfonamides | 2005 |
[Pharmacological and clinical profile of rosuvastatin calcium (Crestor)].
Topics: Animals; Cholesterol; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrimidines; Rats; Rosuvastatin Calcium; Sulfonamides | 2005 |
[Treatment of chronic heart failure. The time of statins?].
Topics: Aged; Animals; Anticholesteremic Agents; Cholesterol; Controlled Clinical Trials as Topic; Costs and Cost Analysis; Disease Models, Animal; Female; Fluorobenzenes; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Male; Prognosis; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Time Factors | 2005 |
An overview of statin-associated proteinuria.
Topics: Animals; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Kidney; Proteins; Proteinuria; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2006 |
How safe is aggressive statin therapy?
Topics: Atorvastatin; Chemical and Drug Induced Liver Injury; Drug Interactions; Drug-Related Side Effects and Adverse Reactions; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Muscular Diseases; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2006 |
Comparison of low-density lipoprotein cholesterol reduction after switching patients on other statins to rosuvastatin or simvastatin in a real-world clinical practice setting.
Topics: Atorvastatin; Cholesterol, LDL; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Medical Records Systems, Computerized; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2007 |
An evaluation of rosuvastatin: pharmacokinetics, clinical efficacy and tolerability.
Topics: Absorption; Atherosclerosis; Cholesterol, LDL; Cytochrome P-450 CYP3A; Drug Interactions; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Liver-Specific Organic Anion Transporter 1; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2008 |
Statin therapy and reductions in low-density lipoprotein cholesterol: initial clinical data on the potent new statin Rosuvastatin.
Topics: Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Dose-Response Relationship, Drug; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Prognosis; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2001 |
Therapies on the horizon for cholesterol reduction.
Topics: Acetamides; Acetates; Anticholesteremic Agents; Azetidines; Carrier Proteins; Cholestyramine Resin; Ezetimibe; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hydroxysteroid Dehydrogenases; Hypercholesterolemia; Membrane Glycoproteins; Pyrimidines; Rosuvastatin Calcium; Sterol O-Acyltransferase; Sulfonamides; Sulfonic Acids | 2001 |
A new statin: a new standard.
Topics: Anticholesteremic Agents; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Drug Administration Schedule; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrimidines; Quality of Health Care; Rosuvastatin Calcium; Sulfonamides | 2001 |
Rosuvastatin for the treatment of patients with hypercholesterolemia.
Topics: Anticholesteremic Agents; Clinical Trials as Topic; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipoproteinemia Type II; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2002 |
Optimizing the pharmacology of statins: characteristics of rosuvastatin.
Topics: Cholesterol, LDL; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2002 |
116 trial(s) available for fluorobenzenes and Elevated Cholesterol
| Article | Year |
|---|---|
Comparison of efficiency between Rosuvastatin and Atorvastatin in reducing low-density lipoprotein (LDL-C) in patients with diabetes mellitus.
Topics: Atorvastatin; Cholesterol, LDL; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2022 |
Intensive lipid-lowering therapy for slowing progression as well as inducing regression of atherosclerosis in Japanese patients: subanalysis of the JART study.
Topics: Aged; Anticholesteremic Agents; Atherosclerosis; Carotid Intima-Media Thickness; Cholesterol, HDL; Cholesterol, LDL; Disease Progression; Female; Fluorobenzenes; Humans; Hypercholesterolemia; Japan; Lipid Metabolism; Male; Middle Aged; Outcome Assessment, Health Care; Pharmacovigilance; Pravastatin; Preventive Health Services; Pyrimidines; Risk Assessment; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2013 |
Achieving recommended low density lipoprotein cholesterol goals and the factors associated with target achievement of hypercholesterolemia patients with rosuvastatin in primary care.
Topics: Cardiovascular Diseases; Cholesterol, LDL; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Male; Middle Aged; Prospective Studies; Pyrimidines; Republic of Korea; Retrospective Studies; Risk Factors; Rosuvastatin Calcium; Smoking; Sulfonamides; Surveys and Questionnaires | 2013 |
Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Atorvastatin; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cholesterol; Cohort Studies; Cytochrome P-450 CYP3A; Databases, Factual; Female; Fluorobenzenes; Genotype; Heptanoic Acids; Humans; Hydroxycholesterols; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Linear Models; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Neoplasm Proteins; Organic Anion Transporters; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Prospective Studies; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Sulfonamides | 2013 |
Impact of the JUPITER trial on statin prescribing for primary prevention.
Topics: Aged; Cohort Studies; Cross-Sectional Studies; Drug Prescriptions; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Ontario; Population Surveillance; Primary Prevention; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2014 |
Efficacy of combination of Ezetimibe 10 mg and rosuvastatin 2.5 mg versus rosuvastatin 5 mg monotherapy for hypercholesterolemia in patients with type 2 diabetes.
Topics: Aged; Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Ezetimibe; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoproteins, LDL; Male; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Triglycerides | 2013 |
Efficacy and safety of ezetimibe added to atorvastatin versus atorvastatin uptitration or switching to rosuvastatin in patients with primary hypercholesterolemia.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hypercholesterolemia; Logistic Models; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2013 |
Rationale and design of the EPISTEME trial: efficacy of post-stroke intensive rosuvastatin treatment for aortogenic embolic stroke.
Topics: Aorta; Brain Ischemia; Echocardiography, Transesophageal; Embolism; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Plaque, Atherosclerotic; Prospective Studies; Pyrimidines; Research Design; Rosuvastatin Calcium; Stroke; Sulfonamides | 2014 |
Comparison of the effect of simvastatin versus simvastatin/ezetimibe versus rosuvastatin on markers of inflammation and oxidative stress in subjects with hypercholesterolemia.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Adult; Aged; Azetidines; Cholesterol, LDL; Dinoprost; Drug Combinations; Ezetimibe; Female; Fluorobenzenes; Humans; Hypercholesterolemia; Lipoproteins, LDL; Male; Middle Aged; Oxidative Stress; Pyrimidines; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2013 |
Efficacy, safety and effect on biomarkers related to cholesterol and lipoprotein metabolism of rosuvastatin 10 or 20 mg plus ezetimibe 10 mg vs. simvastatin 40 or 80 mg plus ezetimibe 10 mg in high-risk patients: Results of the GRAVITY randomized study.
Topics: Absorption; Adult; Atherosclerosis; Azetidines; Biomarkers; Cholesterol, LDL; Coronary Disease; Drug Administration Schedule; Ezetimibe; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Lipoproteins; Male; Pyrimidines; Risk; Rosuvastatin Calcium; Simvastatin; Sitosterols; Sulfonamides; Treatment Outcome | 2014 |
Anti-sympathetic action enhances statin's pleiotropic effects: the combined effect of rosuvastatin and atenolol on endothelial function.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Antihypertensive Agents; Atenolol; Biomarkers; Brachial Artery; Cholesterol, LDL; Drug Interactions; Drug Therapy, Combination; Endothelium, Vascular; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Japan; Male; Middle Aged; Prospective Studies; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Time Factors; Treatment Outcome; Vasodilation; Vasodilator Agents | 2014 |
N-of-1 (single-patient) trials for statin-related myalgia.
Topics: Aged; Aged, 80 and over; Atorvastatin; Double-Blind Method; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Myalgia; Pyrimidines; Pyrroles; Research Design; Rosuvastatin Calcium; Sulfonamides | 2014 |
Effect of rosuvastatin on non-alcoholic steatohepatitis in patients with metabolic syndrome and hypercholesterolaemia: a preliminary report.
Topics: Adult; Biopsy; Drug Administration Schedule; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Liver; Liver Function Tests; Male; Metabolic Syndrome; Non-alcoholic Fatty Liver Disease; Prospective Studies; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Time Factors | 2014 |
Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Atorvastatin; Azetidines; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2014 |
Differences between rosuvastatin and atorvastatin in lipid-lowering action and effect on glucose metabolism in Japanese hypercholesterolemic patients with concurrent diabetes. Lipid-lowering with highly potent statins in hyperlipidemia with type 2 diabete
Topics: Asian People; Atorvastatin; Blood Glucose; Cholesterol, HDL; Diabetes Mellitus; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Follow-Up Studies; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Japan; Male; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2014 |
Efficacy and safety of alirocumab as add-on therapy in high-cardiovascular-risk patients with hypercholesterolemia not adequately controlled with atorvastatin (20 or 40 mg) or rosuvastatin (10 or 20 mg): design and rationale of the ODYSSEY OPTIONS Studies
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2014 |
Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial.
Topics: Acute Coronary Syndrome; Angina, Unstable; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Fluorobenzenes; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Myocardial Infarction; Proprotein Convertase 9; Proprotein Convertases; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Serine Endopeptidases; Stroke; Sulfonamides; Treatment Outcome | 2014 |
Impact of enhanced compliance initiatives on the efficacy of rosuvastatin in reducing low density lipoprotein cholesterol levels in patients with primary hypercholesterolaemia.
Topics: Aged; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoproteins, LDL; Male; Middle Aged; Patient Compliance; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Switzerland; Treatment Outcome | 2008 |
Effects of low-dose atorvastatin and rosuvastatin on plasma lipid profiles: a long-term, randomized, open-label study in patients with primary hypercholesterolemia.
Topics: Adult; Aged; Atorvastatin; Cholesterol; Cholesterol, LDL; Female; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Triglycerides | 2008 |
Effects of lipid-lowering therapy with rosuvastatin on atherosclerotic burden in patients with chronic kidney disease.
Topics: Aged; Atherosclerosis; Cholesterol, LDL; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Kidney Failure, Chronic; Male; Middle Aged; Prospective Studies; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Tunica Intima | 2008 |
Effect of statins on soluble CD40 ligand in hypercholesterolemic Type 2 diabetic patients.
Topics: Albumins; Biomarkers; Blood Pressure; CD40 Ligand; Diabetes Mellitus, Type 2; Female; Fluorobenzenes; Homocysteine; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Interleukin-6; Lipids; Male; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2008 |
Discovery Belux: comparison of rosuvastatin with atorvastatin in hypercholesterolaemia.
Topics: Atorvastatin; Belgium; Cholesterol, LDL; Female; Fluorobenzenes; Health Status Indicators; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Logistic Models; Male; Markov Chains; Middle Aged; Models, Statistical; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2008 |
LDL-cholesterol lowering increases plasma apelin in isolated hypercholesterolemia.
Topics: Adiponectin; Adult; Apelin; Biomarkers; C-Reactive Protein; Cholesterol, LDL; Diet; Exercise; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Insulin; Intercellular Signaling Peptides and Proteins; Leptin; Male; Middle Aged; Pyrimidines; Risk Reduction Behavior; Rosuvastatin Calcium; Sulfonamides; Time Factors; Treatment Outcome; Tumor Necrosis Factor-alpha | 2009 |
Rosuvastatin, pravastatin, and atorvastatin for the treatment of hypercholesterolaemia in HIV-infected patients receiving protease inhibitors.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Cholesterol; Female; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; HIV Infections; HIV Protease Inhibitors; Humans; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Viral Load | 2008 |
Rationale and design of the carotid plaque in human for all evaluations with aggressive rosuvastatin therapy (CHALLENGER trial): evaluation by magnetic resonance imaging.
Topics: Angiography; Carotid Stenosis; Cholesterol, LDL; Dose-Response Relationship, Drug; Endpoint Determination; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Japan; Longitudinal Studies; Magnetic Resonance Imaging; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Tunica Intima; Tunica Media | 2009 |
Superior benefit of aggressive lipid-lowering therapy for high- risk patients using statins: the SUBARU study--more hypercholesterolemic patients achieve Japan Atherosclerosis Society LDL-C goals with rosuvastatin therapy than with atorvastatin therapy.
Topics: Adult; Aged; Aged, 80 and over; Atherosclerosis; Atorvastatin; Blood Glucose; Cholesterol, HDL; Cholesterol, LDL; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Japan; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2008 |
Effect of atorvastatin versus rosuvastatin on levels of serum lipids, inflammatory markers and adiponectin in patients with hypercholesterolemia.
Topics: Adiponectin; Adult; Aged; Atorvastatin; Biomarkers; Brachial Artery; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Inflammation Mediators; Lipids; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Time Factors; Treatment Outcome; Vasodilation; Vasodilator Agents | 2009 |
Should high creatine kinase discourage the initiation or continuance of statins for the treatment of hypercholesterolemia?
Topics: Atorvastatin; Cholesterol, LDL; Creatine Kinase; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Rhabdomyolysis; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2009 |
Influence of short-term rosuvastatin therapy on endothelial progenitor cells and endothelial function.
Topics: Cholesterol; Drug Administration Schedule; Endothelial Cells; Endothelium, Vascular; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Prospective Studies; Pyrimidines; Rosuvastatin Calcium; Stem Cells; Sulfonamides; Treatment Outcome; Vasodilation | 2009 |
Impact of a compliance program on cholesterol control: results of the randomized ORBITAL study in 8108 patients treated with rosuvastatin.
Topics: Aged; Biomarkers; Cholesterol, LDL; Europe; Female; Fluorobenzenes; Health Knowledge, Attitudes, Practice; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Medication Adherence; Middle Aged; Patient Education as Topic; Program Evaluation; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Time Factors; Treatment Outcome | 2009 |
Efficacy of alternate day versus daily dosing of rosuvastatin.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cholesterol, HDL; Cholesterol, LDL; Confidence Intervals; Cross-Over Studies; Drug Administration Schedule; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Patient Compliance; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Triglycerides; Young Adult | 2009 |
Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared with rosuvastatin 10 mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy - The IN-CROSS study.
Topics: Adult; Aged; Aged, 80 and over; Azetidines; Cholesterol, LDL; Coronary Artery Disease; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2009 |
Intensive lipid lowering may reduce progression of carotid atherosclerosis within 12 months of treatment: the METEOR study.
Topics: Aged; Anticholesteremic Agents; Carotid Artery Diseases; Cholesterol, LDL; Disease Progression; Double-Blind Method; Female; Fluorobenzenes; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Time Factors; Treatment Outcome; Tunica Intima; Ultrasonography | 2009 |
Achieving lipid goals with rosuvastatin compared with simvastatin in high risk patients in real clinical practice: a randomized, open-label, parallel-group, multi-center study: the DISCOVERY-Beta study.
Topics: Aged; Cardiovascular Diseases; Estonia; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Male; Middle Aged; Practice Guidelines as Topic; Pyrimidines; Risk Assessment; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Time Factors; Treatment Outcome | 2008 |
Adding exercise training to rosuvastatin treatment: influence on serum lipids and biomarkers of muscle and liver damage.
Topics: Adult; Aged; Alanine Transaminase; Anticholesteremic Agents; Cholesterol; Creatine Kinase; Exercise; Female; Fluorobenzenes; Humans; Hypercholesterolemia; Lipids; Lipoproteins, LDL; Male; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Triglycerides | 2009 |
Predicting benefit from statins by C-reactive protein, LDL-cholesterol or absolute cardiovascular risk.
Topics: Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Confidence Intervals; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrimidines; Risk; Risk Assessment; Risk Factors; Risk Reduction Behavior; Rosuvastatin Calcium; Sulfonamides; Venous Thromboembolism | 2009 |
Usefulness of aggressive lipid-lowering therapy with rosuvastatin in hypercholesterolemic patients with concomitant type 2 diabetes.
Topics: Aged; Atorvastatin; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Lipids; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2009 |
Rosuvastatin increased serum osteocalcin levels independent of its serum cholesterol-lowering effect in patients with type 2 diabetes and hypercholesterolemia.
Topics: Aged; Alkaline Phosphatase; Amino Acids; Azetidines; Bone and Bones; Cholesterol; Cholesterol, LDL; Collagen Type I; Diabetes Mellitus, Type 2; Ezetimibe; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Osteocalcin; Peptides; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2009 |
One-year treatment with rosuvastatin reduces intima-media thickness in 45 hypercholesterolemic subjects with asymptomatic carotid artery disease.
Topics: Atherosclerosis; Carotid Artery Diseases; Cross-Sectional Studies; Female; Fluorobenzenes; Humans; Hypercholesterolemia; Male; Middle Aged; Prospective Studies; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Time Factors; Tunica Intima; Tunica Media | 2010 |
ABCG2 polymorphism is associated with the low-density lipoprotein cholesterol response to rosuvastatin.
Topics: Adult; Aged; Asian People; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cholesterol, LDL; Double-Blind Method; Female; Fluorobenzenes; Follow-Up Studies; Humans; Hypercholesterolemia; Male; Middle Aged; Neoplasm Proteins; Polymorphism, Single Nucleotide; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2010 |
Comparative study of low doses of rosuvastatin and atorvastatin on lipid and glycemic control in patients with metabolic syndrome and hypercholesterolemia.
Topics: Atorvastatin; Blood Glucose; Cholesterol, LDL; Female; Fluorobenzenes; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperglycemia; Insulin; Male; Metabolic Syndrome; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2010 |
Incremental cholesterol reduction with ezetimibe/simvastatin, atorvastatin and rosuvastatin in UK General Practice (IN-PRACTICE): randomised controlled trial of achievement of Joint British Societies (JBS-2) cholesterol targets.
Topics: Aged; Analysis of Variance; Anticholesteremic Agents; Atorvastatin; Azetidines; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Fluorobenzenes; General Practice; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Secondary Prevention; Simvastatin; Sulfonamides; Treatment Outcome | 2010 |
Efficacy and safety of rosuvastatin and fenofibric acid combination therapy versus simvastatin monotherapy in patients with hypercholesterolemia and hypertriglyceridemia: a randomized, double-blind study.
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Female; Fenofibrate; Fluorobenzenes; Humans; Hypercholesterolemia; Hypertriglyceridemia; Liver; Male; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2010 |
Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared to rosuvastatin 10 mg in high-risk patients with and without type 2 diabetes mellitus inadequately controlled despite prior statin monotherapy.
Topics: Anticholesteremic Agents; Apolipoproteins B; Azetidines; C-Reactive Protein; Cholesterol; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Resistance; Drug Therapy, Combination; Ezetimibe; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Odds Ratio; Pyrimidines; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2012 |
Ezetimibe/simvastatin 10/20 mg versus rosuvastatin 10 mg in high-risk hypercholesterolemic patients stratified by prior statin treatment potency.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Azetidines; Ezetimibe; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome; Young Adult | 2010 |
Effects of atorvastatin and rosuvastatin on thromboxane-dependent platelet activation and oxidative stress in hypercholesterolemia.
Topics: 3' Untranslated Regions; Anticholesteremic Agents; Atorvastatin; Blood Platelets; Double-Blind Method; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hypercholesterolemia; Lipids; Male; Middle Aged; Oxidative Stress; Platelet Activation; Polymorphism, Genetic; Prospective Studies; Prostaglandins A; Pyrimidines; Pyrroles; Regression Analysis; Rosuvastatin Calcium; Sulfonamides; Thromboxane B2 | 2011 |
Comparison of effects of rosuvastatin and atorvastatin on plaque regression in Korean patients with untreated intermediate coronary stenosis.
Topics: Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Coronary Angiography; Coronary Artery Disease; Coronary Stenosis; Disease Progression; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Korea; Male; Plaque, Atherosclerotic; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Ultrasonography, Interventional | 2011 |
Different effects of rosuvastatin and simvastatin on myocardial high-energy phosphate metabolism.
Topics: Adult; Aged; Energy Metabolism; Fluorobenzenes; Humans; Hypercholesterolemia; Male; Middle Aged; Myocardium; Phosphates; Pyrimidines; Rosuvastatin Calcium; Simvastatin; Single-Blind Method; Sulfonamides | 2011 |
Switching from statin monotherapy to ezetimibe/simvastatin or rosuvastatin modifies the relationships between apolipoprotein B, LDL cholesterol, and non-HDL cholesterol in patients at high risk of coronary disease.
Topics: Aged; Apolipoproteins B; Azetidines; Cholesterol; Coronary Disease; Ezetimibe; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2011 |
Randomized head-to-head comparison of pitavastatin, atorvastatin, and rosuvastatin for safety and efficacy (quantity and quality of LDL): the PATROL trial.
Topics: Aged; Analysis of Variance; Atorvastatin; Biomarkers; Cholesterol, LDL; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Japan; Male; Middle Aged; Patient Selection; Prospective Studies; Pyrimidines; Pyrroles; Quinolines; Rosuvastatin Calcium; Sulfonamides; Time Factors; Treatment Outcome | 2011 |
Safety and efficacy of ezetimibe added on to rosuvastatin 5 or 10 mg versus up-titration of rosuvastatin in patients with hypercholesterolemia (the ACTE Study).
Topics: Aged; Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2011 |
The role of soluble fiber intake in patients under highly effective lipid-lowering therapy.
Topics: Azetidines; Blood Glucose; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Dietary Fiber; Ezetimibe; Female; Fluorobenzenes; Humans; Hypercholesterolemia; Intestinal Diseases; Lipid Metabolism, Inborn Errors; Male; Middle Aged; Phytosterols; Pyrimidines; Rosuvastatin Calcium; Sitosterols; Sulfonamides; Triglycerides | 2011 |
Lipid-altering efficacy of switching to ezetimibe/simvastatin 10/20 mg versus rosuvastatin 10 mg in high-risk patients with and without metabolic syndrome.
Topics: Aged; Analysis of Variance; Anticholesteremic Agents; Apolipoproteins B; Azetidines; Biomarkers; Cholesterol; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Drug Combinations; Drug Substitution; Europe; Ezetimibe, Simvastatin Drug Combination; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Least-Squares Analysis; Lipids; Logistic Models; Male; Metabolic Syndrome; Middle Aged; Odds Ratio; Pyrimidines; Risk Assessment; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2011 |
Comparison of the effects of simvastatin vs. rosuvastatin vs. simvastatin/ezetimibe on parameters of insulin resistance.
Topics: Aged; Azetidines; Blood Glucose; Body Mass Index; Cholesterol, LDL; Drug Combinations; Ezetimibe; Fasting; Female; Fluorobenzenes; Homeostasis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Insulin Resistance; Male; Medication Adherence; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2011 |
Effect of 2-year treatment with low-dose rosuvastatin on intima-media thickness in hypercholesterolemic subjects with asymptomatic carotid artery disease.
Topics: Carotid Artery Diseases; Carotid Intima-Media Thickness; Cholesterol; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Triglycerides | 2011 |
Effect of intensive lipid-lowering therapy with rosuvastatin on progression of carotid intima-media thickness in Japanese patients: Justification for Atherosclerosis Regression Treatment (JART) study.
Topics: Aged; Asian People; Carotid Artery Diseases; Carotid Intima-Media Thickness; Cholesterol, HDL; Cholesterol, LDL; Disease Progression; Female; Fluorobenzenes; Humans; Hypercholesterolemia; Hypolipidemic Agents; Japan; Longitudinal Studies; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrimidines; Rosuvastatin Calcium; Single-Blind Method; Sulfonamides; Time Factors; Treatment Outcome | 2012 |
Differential metabolic effects of rosuvastatin and pravastatin in hypercholesterolemic patients.
Topics: Female; Fluorobenzenes; Glycated Hemoglobin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Insulin Resistance; Male; Middle Aged; Pravastatin; Pyrimidines; Rosuvastatin Calcium; Single-Blind Method; Sulfonamides | 2013 |
[Randomized head-to-head comparison of pitavastatin, atorvastatin, and rosuvastatin for safety and efficacy (quantity and quality of LDL): -- the PATROL trial].
Topics: Atorvastatin; Cholesterol, LDL; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrimidines; Pyrroles; Quinolines; Rosuvastatin Calcium; Sulfonamides | 2011 |
Rosuvastatin improves pulse wave reflection by restoring endothelial function.
Topics: Angiography; Blood Pressure; Cross-Over Studies; Elasticity; Endothelium, Vascular; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Microcirculation; Microvessels; Middle Aged; Nitric Oxide Synthase Type III; omega-N-Methylarginine; Pulsatile Flow; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2012 |
Differences in synthesis and absorption of cholesterol of two effective lipid-lowering therapies.
Topics: Adult; Aged; Anticholesteremic Agents; Azetidines; Biomarkers; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Prospective Studies; Pyrimidines; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2012 |
High HbA1c levels correlate with reduced plaque regression during statin treatment in patients with stable coronary artery disease: results of the coronary atherosclerosis study measuring effects of rosuvastatin using intravascular ultrasound in Japanese
Topics: Aged; Asian People; Biomarkers; Chi-Square Distribution; Coronary Artery Disease; Coronary Vessels; Female; Fluorobenzenes; Glycated Hemoglobin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Japan; Linear Models; Lipids; Male; Middle Aged; Multivariate Analysis; Plaque, Atherosclerotic; Pyrimidines; Risk Assessment; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Time Factors; Treatment Outcome; Ultrasonography, Interventional | 2012 |
Colesevelam plus rosuvastatin 5 mg/day versus rosuvastatin 10 mg/day alone on markers of insulin resistance in patients with hypercholesterolemia and impaired fasting glucose.
Topics: Aged; Allylamine; Anticholesteremic Agents; Biomarkers; Blood Glucose; Colesevelam Hydrochloride; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Fasting; Female; Fluorobenzenes; Glucose Intolerance; Humans; Hypercholesterolemia; Insulin Resistance; Male; Middle Aged; Prediabetic State; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2013 |
Alteration of relation of atherogenic lipoprotein cholesterol to apolipoprotein B by intensive statin therapy in patients with acute coronary syndrome (from the Limiting UNdertreatment of lipids in ACS With Rosuvastatin [LUNAR] Trial).
Topics: Acute Coronary Syndrome; Aged; Apolipoproteins B; Cholesterol; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoproteins; Male; Middle Aged; Prospective Studies; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2013 |
Angiotensin II type 1 and type 2 receptor expression in circulating monocytes of diabetic and hypercholesterolemic patients over 3-month rosuvastatin treatment.
Topics: Aged; Diabetes Mellitus, Type 2; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Monocytes; Pyrimidines; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Rosuvastatin Calcium; Sulfonamides | 2012 |
25-hydroxyvitamin D insufficiency is associated with impaired renal endothelial function and both are improved with rosuvastatin treatment.
Topics: Adult; Aged; Cross-Over Studies; Double-Blind Method; Endothelium, Vascular; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Nitric Oxide; Nitric Oxide Synthase; omega-N-Methylarginine; Pyrimidines; Regression Analysis; Rosuvastatin Calcium; Sulfonamides; Vitamin D; Vitamin D Deficiency | 2013 |
A comparison of efficacy and safety of an ezetimibe/simvastatin combination compared with other intensified lipid-lowering treatment strategies in diabetic patients with symptomatic cardiovascular disease.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Complications; Diabetic Angiopathies; Double-Blind Method; Drug Combinations; Drug Monitoring; Ezetimibe, Simvastatin Drug Combination; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hypercholesterolemia; Longitudinal Studies; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Severity of Illness Index; Simvastatin; Sulfonamides | 2013 |
Clinical effects of rosuvastatin, a new HMG-CoA reductase inhibitor, in Japanese patients with primary hypercholesterolemia: an early phase II study.
Topics: Adult; Aged; Cholesterol; Double-Blind Method; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Japan; Male; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2002 |
Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: a randomized, double-blind, 52-week trial.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Cholesterol, LDL; Double-Blind Method; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Pyrimidines; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2002 |
Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Double-Blind Method; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2002 |
Comparative effects of rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial disease.
Topics: Anticholesteremic Agents; Apolipoproteins; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hypercholesterolemia; Linear Models; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2003 |
Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Drug Administration Schedule; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Least-Squares Analysis; Male; Middle Aged; Multicenter Studies as Topic; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2003 |
Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Drug Administration Schedule; Europe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Multicenter Studies as Topic; Practice Guidelines as Topic; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Risk; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2003 |
Lipid and apolipoprotein ratios: association with coronary artery disease and effects of rosuvastatin compared with atorvastatin, pravastatin, and simvastatin.
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoproteins; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Europe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Least-Squares Analysis; Lipids; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2003 |
Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Cholesterol, LDL; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Time Factors | 2003 |
Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; North America; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2003 |
Randomized dose-response study of rosuvastatin in Japanese patients with hypercholesterolemia.
Topics: Adult; Aged; Cholesterol, LDL; Dose-Response Relationship, Drug; Double-Blind Method; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Japan; Male; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Safety; Sulfonamides; Triglycerides | 2003 |
Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study.
Topics: Aged; Arteriosclerosis; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus, Type 2; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Logistic Models; Male; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Triglycerides | 2004 |
Comparative evaluation of the efficacy, safety, and tolerability of rosuvastatin 10 mg with atorvastatin 10 mg in adult patients with hypercholesterolaemia: the first Indian study.
Topics: Apolipoproteins B; Atorvastatin; Cholesterol; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2004 |
Efficacy and safety of rosuvastatin and atorvastatin in patients with hypercholesterolemia and a high risk of coronary heart disease: a randomized, controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Apolipoproteins; Atorvastatin; Cholesterol; Double-Blind Method; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Least-Squares Analysis; Logistic Models; Male; Middle Aged; Muscular Diseases; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Triglycerides | 2004 |
Effect of rosuvastatin on plasma levels of asymmetric dimethylarginine in patients with hypercholesterolemia.
Topics: Aged; Arginine; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Endothelium, Vascular; Female; Fluorobenzenes; Homocysteine; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Vasodilation | 2004 |
Pharmacodynamic interaction between ezetimibe and rosuvastatin.
Topics: Adult; Anticholesteremic Agents; Azetidines; Drug Synergism; Drug Therapy, Combination; Ezetimibe; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pilot Projects; Pyrimidines; Rosuvastatin Calcium; Single-Blind Method; Sulfonamides; Treatment Outcome | 2004 |
Lipid-modifying effects of rosuvastatin in postmenopausal women with hypercholesterolemia who are receiving hormone replacement therapy.
Topics: Administration, Oral; Aged; Dose-Response Relationship, Drug; Double-Blind Method; Female; Fluorobenzenes; Hormone Replacement Therapy; Humans; Hypercholesterolemia; Lipoproteins; Middle Aged; Placebos; Postmenopause; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2004 |
Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.
Topics: Aged; Anticholesteremic Agents; Apolipoproteins; Atorvastatin; Cholesterol, LDL; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2004 |
Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
Topics: Atorvastatin; Cholesterol, LDL; Coronary Disease; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Triglycerides | 2004 |
Efficacy and safety of rosuvastatin alone and in combination with cholestyramine in patients with severe hypercholesterolemia: a randomized, open-label, multicenter trial.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Cholesterol, LDL; Cholestyramine Resin; Drug Therapy, Combination; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2004 |
Comparative effects of rosuvastatin and gemfibrozil on glucose, insulin, and lipid metabolism in insulin-resistant, nondiabetic patients with combined dyslipidemia.
Topics: Apolipoproteins; Blood Glucose; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Female; Fluorobenzenes; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Insulin; Insulin Resistance; Male; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Triglycerides | 2005 |
Rosuvastatin is cost-effective in treating patients to low-density lipoprotein-cholesterol goals compared with atorvastatin, pravastatin and simvastatin: analysis of the STELLAR trial.
Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Cost-Benefit Analysis; Drug Costs; Economics, Pharmaceutical; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pravastatin; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2005 |
Effects of switching statins on lipid and apolipoprotein ratios in the MERCURY I study.
Topics: Analysis of Variance; Apolipoproteins; Atorvastatin; Coronary Disease; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Male; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Risk; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2005 |
Cholesterol-lowering effects of rosuvastatin compared with atorvastatin in patients with type 2 diabetes -- CORALL study.
Topics: Anticholesteremic Agents; Apolipoprotein A-I; Apolipoproteins A; Apolipoproteins B; Atorvastatin; Diabetes Mellitus, Type 2; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hypercholesterolemia; Lipids; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2005 |
The DISCOVERY PENTA study: a DIrect Statin COmparison of LDL-C Value--an Evaluation of Rosuvastatin therapY compared with atorvastatin.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Program Evaluation; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Triglycerides | 2005 |
A statin in the treatment of heart failure? Controlled rosuvastatin multinational study in heart failure (CORONA): study design and baseline characteristics.
Topics: Age Factors; Aged; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Fluorobenzenes; Follow-Up Studies; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; International Cooperation; Male; Middle Aged; Probability; Prospective Studies; Pyrimidines; Risk Assessment; Rosuvastatin Calcium; Severity of Illness Index; Sulfonamides; Survival Analysis; Treatment Outcome | 2005 |
Achieving lipid goals in real life: the Dutch DISCOVERY study.
Topics: Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Netherlands; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome; Triglycerides | 2005 |
Effect of short-term rosuvastatin treatment on estimated glomerular filtration rate.
Topics: Cholesterol, LDL; Female; Fluorobenzenes; Follow-Up Studies; Glomerular Filtration Rate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrimidines; Retrospective Studies; Rosuvastatin Calcium; Sulfonamides; Time Factors; Treatment Outcome | 2006 |
Rosuvastatin 5 and 10 mg/d: a pilot study of the effects in hypercholesterolemic adults unable to tolerate other statins and reach LDL cholesterol goals with nonstatin lipid-lowering therapies.
Topics: Adult; Aged; Aged, 80 and over; Cholesterol, LDL; Cholinergic Antagonists; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pilot Projects; Prospective Studies; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Triglycerides | 2006 |
Treatment of hypercholesterolemia in patients with metabolic syndrome: how do different statins compare?
Topics: Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Metabolic Syndrome; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2006 |
Comparison of rosuvastatin versus atorvastatin in Hispanic-Americans with hypercholesterolemia (from the STARSHIP trial).
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Female; Fluorobenzenes; Heptanoic Acids; Hispanic or Latino; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2006 |
Efficacy and safety of rosuvastatin every other day compared with once daily in patients with hypercholesterolemia.
Topics: Adult; Aged; Aged, 80 and over; Drug Administration Schedule; Female; Fluorobenzenes; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2006 |
Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients.
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Double-Blind Method; Drug Combinations; Ezetimibe, Simvastatin Drug Combination; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Tablets | 2006 |
Effects of rosuvastatin on 3-nitrotyrosine and aortic stiffness in hypercholesterolemia.
Topics: Adult; Aged; Aorta; Cholesterol; Combined Modality Therapy; Compliance; Diet, Fat-Restricted; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Prospective Studies; Pulsatile Flow; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Tyrosine | 2007 |
Efficacy and safety of rosuvastatin 40 mg versus atorvastatin 80 mg in high-risk patients with hypercholesterolemia: results of the POLARIS study.
Topics: Aged; Atorvastatin; Cholesterol, LDL; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2007 |
Rosuvastatin improves basal nitric oxide activity of the renal vasculature in patients with hypercholesterolemia.
Topics: Adolescent; Adult; Aged; Blood Pressure; Cholesterol, LDL; Cross-Over Studies; Double-Blind Method; Endothelium, Vascular; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Kidney; Male; Middle Aged; Nitric Oxide Synthase; omega-N-Methylarginine; Pyrimidines; Regional Blood Flow; Renal Circulation; Rosuvastatin Calcium; Sulfonamides; Time Factors | 2008 |
Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study).
Topics: Aged; Azetidines; Cardiovascular Diseases; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ezetimibe; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2007 |
Comparison of the effects of high doses of rosuvastatin versus atorvastatin on the subpopulations of high-density lipoproteins.
Topics: Adult; Aged; Apolipoprotein A-I; Atorvastatin; Cholesterol; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoproteins, HDL; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Triglycerides | 2007 |
Comparison of rosuvastatin versus atorvastatin in South-Asian patients at risk of coronary heart disease (from the IRIS Trial).
Topics: Adult; Aged; Analysis of Variance; Anticholesteremic Agents; Apolipoprotein A-I; Asian People; Atorvastatin; Biomarkers; Canada; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; United States | 2007 |
Statin's cost-effectiveness: a Canadian analysis of commonly prescribed generic and brand name statins.
Topics: Adult; Atorvastatin; Canada; Cholesterol, LDL; Cost-Benefit Analysis; Drug Costs; Drugs, Generic; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Insurance, Pharmaceutical Services; Male; Models, Economic; Practice Guidelines as Topic; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2007 |
[The efficacy and safety of rosuvastatin on treating patients with hypercholesterolemia in Chinese: a randomized, double-blind, multi-center clinical trial].
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Asian People; Atorvastatin; Double-Blind Method; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hypercholesterolemia; Hypolipidemic Agents; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Young Adult | 2007 |
Early impairment of left ventricular function in hypercholesterolemia and its reversibility after short term treatment with rosuvastatin A preliminary echocardiographic study.
Topics: Adult; Blood Flow Velocity; Densitometry; Diastole; Echocardiography, Doppler, Color; Fluorobenzenes; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Middle Aged; Pilot Projects; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Systole; Ventricular Dysfunction, Left | 2008 |
Indices of reverse cholesterol transport in subjects with metabolic syndrome after treatment with rosuvastatin.
Topics: Adult; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cross-Over Studies; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Metabolic Syndrome; Middle Aged; Phosphatidylcholine-Sterol O-Acyltransferase; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2008 |
Comparison of effectiveness of rosuvastatin versus atorvastatin on the achievement of combined C-reactive protein (<2 mg/L) and low-density lipoprotein cholesterol (< 70 mg/dl) targets in patients with type 2 diabetes mellitus (from the ANDROMEDA study).
Topics: Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; England; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; North Carolina; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2007 |
Long-term efficacy and safety of rosuvastatin 40 mg in patients with severe hypercholesterolemia.
Topics: Adult; Alanine Transaminase; Cholesterol, HDL; Cholesterol, LDL; Creatinine; Female; Fluorobenzenes; Glomerular Filtration Rate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipoproteinemia Type II; Liver Function Tests; Male; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2007 |
A randomised study comparing the efficacy and safety of rosuvastatin with atorvastatin for achieving lipid goals in clinical practice in Asian patients at high risk of cardiovascular disease (DISCOVERY-Asia study).
Topics: Anticholesteremic Agents; Asia; Atorvastatin; Cardiovascular Diseases; Cholesterol; Cholesterol, LDL; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Sulfonamides | 2007 |
Effect of rosuvastatin therapy on carotid plaque morphology and composition in moderately hypercholesterolemic patients: a high-resolution magnetic resonance imaging trial.
Topics: Aged; Carotid Arteries; Carotid Artery Diseases; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Female; Fluorobenzenes; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Magnetic Resonance Imaging; Male; Middle Aged; Pyrimidines; Reproducibility of Results; Retrospective Studies; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2008 |
Efficacy and tolerability of rosuvastatin and atorvastatin when force-titrated in patients with primary hypercholesterolemia: results from the ECLIPSE study.
Topics: Aged; Atorvastatin; Canada; Cholesterol, LDL; Coronary Disease; European Union; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrimidines; Pyrroles; Risk Assessment; Risk Factors; Rosuvastatin Calcium; Sulfonamides | 2008 |
Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrimidines; Pyrroles; Reference Values; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2001 |
Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia.
Topics: Anticholesteremic Agents; Apolipoproteins; Atorvastatin; Canada; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diet; Double-Blind Method; Drug Administration Schedule; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Triglycerides; United States | 2002 |
Rosuvastatin demonstrates greater reduction of low-density lipoprotein cholesterol compared with pravastatin and simvastatin in hypercholesterolaemic patients: a randomized, double-blind study.
Topics: Cholesterol, LDL; Double-Blind Method; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Pyrimidines; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2001 |
90 other study(ies) available for fluorobenzenes and Elevated Cholesterol
| Article | Year |
|---|---|
[Atorvastatin-induced anemia accompanied by elevated serum LDH levels].
Topics: Aged; Anemia; Atorvastatin; Cholesterol, LDL; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Simvastatin | 2020 |
Pharmacokinetic/Pharmacodynamic Modelling to Describe the Cholesterol Lowering Effect of Rosuvastatin in People Living with HIV.
Topics: Anti-Retroviral Agents; Cholesterol; Cholesterol, HDL; Female; Fluorobenzenes; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Rosuvastatin Calcium | 2021 |
Strategies to lower low-density lipoprotein cholesterol in metabolic syndrome: averting the diabetes risk.
Topics: Allylamine; Anticholesteremic Agents; Colesevelam Hydrochloride; Female; Fluorobenzenes; Glucose Intolerance; Humans; Hypercholesterolemia; Insulin Resistance; Male; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2013 |
Statins work around the world.
Topics: Cardiovascular Diseases; Cholesterol, LDL; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2013 |
Statins decrease mean platelet volume irrespective of cholesterol lowering effect.
Topics: Adult; Atorvastatin; Cholesterol, LDL; Comorbidity; Coronary Disease; Diabetes Mellitus; Female; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Male; Mean Platelet Volume; Middle Aged; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Sulfonamides | 2013 |
Longitudinal association between body mass index and health-related quality of life.
Topics: Aged; Body Mass Index; Cardiovascular Diseases; Cross-Sectional Studies; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Longitudinal Studies; Male; Middle Aged; Obesity; Pyrimidines; Quality of Life; Risk Factors; Rosuvastatin Calcium; Sulfonamides | 2014 |
Summaries for patients. Treatment trials to determine whether statins are the cause of a patient's discomfort.
Topics: Aged; Aged, 80 and over; Atorvastatin; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Myalgia; Pyrimidines; Pyrroles; Research Design; Rosuvastatin Calcium; Sulfonamides | 2014 |
[Lipid-lowering therapy and patient adherence in the MULTI GAP 2013 trial].
Topics: Adult; Aged; Atherosclerosis; Atorvastatin; Cholesterol, LDL; Databases, Factual; Drug Prescriptions; Drug Therapy, Combination; Female; Fluorobenzenes; Guideline Adherence; Heptanoic Acids; Humans; Hungary; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Insurance, Health; Male; Middle Aged; Patient Compliance; Practice Guidelines as Topic; Practice Patterns, Physicians'; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Surveys and Questionnaires; Treatment Outcome | 2014 |
Rosuvastatin treatment improves arterial stiffness with lowering blood pressure in healthy hypercholesterolemic patients.
Topics: Adult; Blood Pressure; Female; Fluorobenzenes; Health Status; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Vascular Stiffness | 2014 |
N-of-1 (single-patient) trials for statin-related myalgia.
Topics: Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Myalgia; Pyrimidines; Pyrroles; Sulfonamides | 2014 |
N-of-1 (single-patient) trials for statin-related myalgia.
Topics: Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Myalgia; Pyrimidines; Pyrroles; Sulfonamides | 2014 |
A generalised sensation of coldness following introduction of rosuvastatin therapy.
Topics: Cold Temperature; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Sensation; Sulfonamides | 2014 |
Risk of diabetes in patients treated with HMG-CoA reductase inhibitors.
Topics: Aged; Atorvastatin; Diabetes Mellitus; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Quinolines; Retrospective Studies; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2015 |
Giant cell arteritis and polymyalgia rheumatica after reexposure to a statin: a case report.
Topics: Aged; Atorvastatin; Female; Fluorobenzenes; Giant Cell Arteritis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Polymyalgia Rheumatica; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2014 |
Achieving goal lipid levels with ezetimibe plus statin add-on or switch therapy compared with doubling the statin dose. A pooled analysis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Apolipoproteins B; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Dose-Response Relationship, Drug; Double-Blind Method; Ezetimibe; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Male; Middle Aged; Pyrimidines; Randomized Controlled Trials as Topic; Research Design; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome; Young Adult | 2014 |
[Negative effects of termination statinotherapy in patients after acute coronary event with concominent non-alcoholic steatohepatitis].
Topics: Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Drug Administration Schedule; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Myocardial Infarction; Non-alcoholic Fatty Liver Disease; Pyrimidines; Pyrroles; Recurrence; Rosuvastatin Calcium; Sulfonamides; Triglycerides | 2014 |
Transient azoospermia following rosuvastatin medication for hypercholesterolemia.
Topics: Administration, Oral; Adult; Azoospermia; Diagnosis, Differential; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Infertility; Magnetic Resonance Imaging; Male; Middle Aged; Oocyte Retrieval; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Testis | 2015 |
[Aspects of the Efficacy and Safety of Rosuvastatin in Patients at Polymorbid States].
Topics: Cholesterol, LDL; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Rosuvastatin Calcium; Treatment Outcome | 2015 |
Efficacy of rosuvastatin (5 mg and 10 mg) twice a week in patients intolerant to daily statins.
Topics: Administration, Oral; Anticholesteremic Agents; Azetidines; Biological Products; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Dietary Supplements; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Drug Tolerance; Ezetimibe; Female; Fluorobenzenes; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrimidines; Retrospective Studies; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Triglycerides | 2008 |
Cost-effectiveness analysis of rosuvastatin versus atorvastatin, simvastatin, and pravastatin from a Canadian health system perspective.
Topics: Adult; Apolipoprotein A-I; Apolipoproteins B; Atorvastatin; British Columbia; Cholesterol, HDL; Cholesterol, LDL; Cost-Benefit Analysis; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pravastatin; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Triglycerides | 2008 |
Partial recovery of the endothelial glycocalyx upon rosuvastatin therapy in patients with heterozygous familial hypercholesterolemia.
Topics: Adult; Anticholesteremic Agents; Atherosclerosis; Cardiovascular Diseases; Cholesterol, LDL; Dextrans; Endothelium; Fluorobenzenes; Glycocalyx; Heterozygote; Humans; Hypercholesterolemia; Male; Middle Aged; Permeability; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2009 |
Rosuvastatin reduces intima-media thickness in hypercholesterolemic subjects with asymptomatic carotid artery disease: the Asymptomatic Carotid Atherosclerotic Disease in Manfredonia (ACADIM) Study.
Topics: Aged; Atherosclerosis; Carotid Artery Diseases; Cholesterol, HDL; Cholesterol, LDL; Cross-Sectional Studies; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Italy; Middle Aged; Prospective Studies; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Triglycerides; Tunica Intima | 2008 |
[Molecular mechanisms of effects of rosuvastatin on systemic oxidative stress and endogenous inflammation in patients with atherosclerosis].
Topics: Coronary Artery Disease; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Oxidative Stress; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2008 |
Effects of rosuvastatin on electronegative LDL as characterized by capillary isotachophoresis: the ROSARY Study.
Topics: Apolipoproteins; Biomarkers; Cholesterol; Cholesterol, HDL; Coronary Disease; Electrophoresis, Capillary; Female; Fluorobenzenes; Humans; Hypercholesterolemia; Inflammation; Lipoproteins; Lipoproteins, LDL; Male; Middle Aged; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Triglycerides | 2009 |
Effects of statins on vascular endothelial function in hypercholesterolemic patients with type 2 diabetes mellitus: fluvastatin vs. rosuvastatin.
Topics: Antioxidants; Brachial Artery; C-Reactive Protein; Cholesterol; Diabetes Mellitus, Type 2; Endothelium, Vascular; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Ultrasonography; Vasodilation | 2010 |
Rosuvastatin given during reperfusion decreases infarct size and inhibits matrix metalloproteinase-2 activity in normocholesterolemic and hypercholesterolemic rabbits.
Topics: Animals; Doxycycline; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Matrix Metalloproteinase 2; Matrix Metalloproteinase Inhibitors; Myocardial Infarction; Myocardial Reperfusion; Myocardial Reperfusion Injury; Myocardium; Pyrimidines; Rabbits; Rosuvastatin Calcium; Sulfonamides | 2009 |
Reversible acute hepatitis induced by rosuvastatin.
Topics: Chemical and Drug Induced Liver Injury; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Liver Function Tests; Male; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2008 |
Study stirs debate about statin use in those without high cholesterol.
Topics: Aged; Cardiovascular Diseases; Cholesterol; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Primary Prevention; Pyrimidines; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Sulfonamides; United States | 2009 |
Statins and venous thromboembolism: a novel effect of statins?
Topics: Adult; Double-Blind Method; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Incidence; Male; Middle Aged; Multicenter Studies as Topic; Placebos; Pyrimidines; Randomized Controlled Trials as Topic; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Venous Thromboembolism | 2009 |
Cardiac hypertrophy during hypercholesterolemia and its amelioration with rosuvastatin and amlodipine.
Topics: Amlodipine; Animals; Blood Pressure; Body Weight; Calcium Channel Blockers; Cardiomegaly; Cholesterol, Dietary; Disease Models, Animal; Drug Therapy, Combination; Fluorobenzenes; Gene Expression; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Male; Mice; Mice, Knockout; Pyrimidines; Receptors, LDL; Reverse Transcriptase Polymerase Chain Reaction; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2009 |
Effects of rosuvastatin on low-density lipoprotein cholesterol and plasma lipids in Asian patients with hypercholesterolemia.
Topics: Adult; Aged; Aged, 80 and over; Asia; Cholesterol, LDL; Drug Evaluation; Female; Fluorobenzenes; Humans; Hypercholesterolemia; Lipids; Male; Middle Aged; Pyrimidines; Retrospective Studies; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Young Adult | 2009 |
Comparison of incidences of cardiovascular events among new users of different statins: a retrospective observational cohort study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Cardiovascular Diseases; Cohort Studies; Female; Fluorobenzenes; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Incidence; Male; Middle Aged; Netherlands; Pyrimidines; Retrospective Studies; Rosuvastatin Calcium; Sulfonamides; Time Factors; Young Adult | 2009 |
Rosuvastatin for cardiovascular prevention: too many uncertainties.
Topics: Aged; Angina, Unstable; Anticholesteremic Agents; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Pravastatin; Pyrimidines; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Stroke; Sulfonamides; Uncertainty | 2009 |
Physiogenomic analysis of statin-treated patients: domain-specific counter effects within the ACACB gene on low-density lipoprotein cholesterol?
Topics: Acetyl-CoA Carboxylase; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, LDL; Cross-Sectional Studies; Female; Fluorobenzenes; Genotype; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Polymorphism, Single Nucleotide; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2010 |
Cost-effectiveness of rosuvastatin for primary prevention of cardiovascular events according to Framingham Risk Score in patients with elevated C-reactive protein.
Topics: C-Reactive Protein; Cardiovascular Diseases; Cost-Benefit Analysis; Diagnosis-Related Groups; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Markov Chains; Models, Statistical; Primary Prevention; Pyrimidines; Quality-Adjusted Life Years; Risk Assessment; Rosuvastatin Calcium; South Dakota; Sulfonamides; United States; United States Food and Drug Administration | 2010 |
[Pharmaco-economic optimization of cholesterol-lowering treatment with statins].
Topics: Atorvastatin; Cholesterol, LDL; Cost-Benefit Analysis; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Goals; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Practice Guidelines as Topic; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Spain; Sulfonamides | 2011 |
Race differences: modeling the pharmacodynamics of rosuvastatin in Western and Asian hypercholesterolemia patients.
Topics: Anticholesteremic Agents; Asia; Asian People; Cholesterol, LDL; Clinical Trials as Topic; Dose-Response Relationship, Drug; Ethnopharmacology; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Models, Biological; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; White People | 2011 |
Improved efficacy for ezetimibe and rosuvastatin by attenuating the induction of PCSK9.
Topics: Animals; Anticholesteremic Agents; Apolipoproteins B; Azetidines; Cholesterol; Cholesterol, LDL; Enzyme-Linked Immunosorbent Assay; Ezetimibe; Fluorobenzenes; Hypercholesterolemia; Mice; Mice, Inbred C57BL; Proprotein Convertase 9; Proprotein Convertases; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Small Interfering; Rosuvastatin Calcium; Serine Endopeptidases; Sulfonamides; Triglycerides | 2011 |
Fish odour syndrome.
Topics: Aged; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Metabolism, Inborn Errors; Methylamines; Oxygenases; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2011 |
Rosuvastatin prevents myocardial necrosis in an experimental model of acute myocardial infarction.
Topics: Animals; Cholesterol, Dietary; Disease Models, Animal; Echocardiography; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Myocardial Infarction; Myocardium; Necrosis; Pyrimidines; Rats; Rats, Wistar; Rosuvastatin Calcium; Sulfonamides | 2011 |
[Fibrillary nonamyloid glomerulonephritis: a rare etiology of nephrotic syndrome].
Topics: Coloring Agents; Complement C3; Congo Red; Diagnosis, Differential; Edema; Female; Fluorobenzenes; Glomerulonephritis; Glomerulosclerosis, Focal Segmental; Humans; Hypercholesterolemia; Immunoglobulin G; Kidney Glomerulus; Losartan; Microscopy, Electron; Middle Aged; Nephrotic Syndrome; Prednisolone; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2011 |
Strong statins as the major players for dyslipidemia in high-risk patients: are they all the same or not?
Topics: Analysis of Variance; Atorvastatin; Biomarkers; Cholesterol, LDL; Evidence-Based Medicine; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Patient Selection; Pyrimidines; Pyrroles; Quinolines; Rosuvastatin Calcium; Sulfonamides; Time Factors; Treatment Outcome | 2011 |
Increased appearance rate of 27-hydroxycholesterol in vivo in hypercholesterolemia: a possible compensatory mechanism.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Case-Control Studies; Cholesterol; Female; Fluorobenzenes; Gas Chromatography-Mass Spectrometry; Heptanoic Acids; Humans; Hydroxycholesterols; Hydroxylation; Hypercholesterolemia; Hyperlipidemia, Familial Combined; Hyperlipoproteinemia Type II; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2012 |
Rosuvastatin therapy does not affect serum MMP-13 or TIMP-1 levels in hypercholesterolemic patients.
Topics: Adult; Aged; Cholesterol, LDL; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Matrix Metalloproteinase 13; Middle Aged; Pilot Projects; Prospective Studies; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Texas; Time Factors; Tissue Inhibitor of Metalloproteinase-1; Treatment Outcome | 2011 |
Soybean glycinin improves HDL-C and suppresses the effects of rosuvastatin on hypercholesterolemic rats.
Topics: Animals; Atherosclerosis; Cholesterol; Cholesterol, Dietary; Cholesterol, HDL; Cholic Acid; Combined Modality Therapy; Dietary Supplements; Fluorobenzenes; Food-Drug Interactions; Globulins; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoproteins; Liver; Male; Pyrimidines; Rats; Rats, Wistar; Risk Factors; Rosuvastatin Calcium; Soybean Proteins; Sulfonamides; Triglycerides | 2011 |
Proprotein convertase substilisin/kexin type 9 antagonism reduces low-density lipoprotein cholesterol in statin-treated hypercholesterolemic nonhuman primates.
Topics: Animals; Antibodies, Monoclonal, Humanized; Catalytic Domain; Cell Line, Tumor; Cholesterol; Cholesterol, Dietary; Cholesterol, HDL; Cholesterol, LDL; Dietary Fats; Dose-Response Relationship, Drug; Drug Therapy, Combination; Epitopes; Female; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Liver; Macaca fascicularis; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Models, Molecular; Primates; Proprotein Convertase 9; Proprotein Convertases; Pyrimidines; Receptors, LDL; Rosuvastatin Calcium; Serine Endopeptidases; Simvastatin; Sulfonamides | 2012 |
Evolution and involution of atherosclerosis and its relationship with vascular reactivity in hypercholesterolemic rabbits.
Topics: Animals; Aorta, Thoracic; Atherosclerosis; Cholesterol, Dietary; Data Interpretation, Statistical; Endothelium, Vascular; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipid Peroxidation; Lipids; Male; Pyrimidines; Rabbits; Rosuvastatin Calcium; Sulfonamides; Time Factors; Vasodilation | 2013 |
Intensive lipid-lowering therapy with statins for primary prevention.
Topics: Asian People; Carotid Artery Diseases; Carotid Intima-Media Thickness; Disease Progression; Female; Fluorobenzenes; Humans; Hypercholesterolemia; Hypolipidemic Agents; Male; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2012 |
β-conglycinin combined with fenofibrate or rosuvastatin have exerted distinct hypocholesterolemic effects in rats.
Topics: Animals; Anticholesteremic Agents; Antigens, Plant; Cholesterol; Diet, High-Fat; Dietary Proteins; Drug Combinations; Drug Synergism; Fenofibrate; Fluorobenzenes; Globulins; Glycine max; Heart; Hypercholesterolemia; Liver; Male; Myocardium; Organ Size; Pyrimidines; Rats; Rats, Wistar; Rosuvastatin Calcium; Seed Storage Proteins; Soybean Proteins; Sulfonamides; Triglycerides | 2012 |
Reversible dysphasia and statins.
Topics: Anticholesteremic Agents; Antihypertensive Agents; Anxiety; Aphasia; Atorvastatin; Cytochrome P-450 Enzyme System; Depression; Drug Interactions; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hypercholesterolemia; Indapamide; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2012 |
The farnesoid X receptor -1G>T polymorphism influences the lipid response to rosuvastatin.
Topics: Alleles; Cholesterol; Female; Fluorobenzenes; Genotype; Humans; Hypercholesterolemia; Male; Middle Aged; Polymorphism, Single Nucleotide; Pyrimidines; Receptors, Cytoplasmic and Nuclear; Rosuvastatin Calcium; Sulfonamides | 2012 |
[Achievement of therapeutic target in subjects on statin treatment in clinical practice. Results of the STAR (Statins Target Assessment in Real practice) study].
Topics: Aged; Algorithms; Azetidines; Biomarkers; Cardiovascular Diseases; Cerebrovascular Disorders; Cholesterol, LDL; Cohort Studies; Diabetes Complications; Diabetes Mellitus; Ezetimibe; Female; Fluorobenzenes; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Italy; Lovastatin; Male; Medication Adherence; Middle Aged; Pravastatin; Pyrimidines; Retrospective Studies; Risk Assessment; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2011 |
[Effectiveness of generic rosuvastatin in patients with ischaemic cerebrovascular disease].
Topics: Aged; Biomarkers; Brain Ischemia; C-Reactive Protein; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Drugs, Generic; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Male; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Triglycerides | 2012 |
Statin resistant dyslipidemia in a patient treated with amiodarone.
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Cholesterol, LDL; Drug Resistance; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypothyroidism; Male; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Thyroxine | 2011 |
Adverse drug reaction: rosuvastatin as a cause for ischaemic colitis in a 64-year-old woman.
Topics: Colitis, Ischemic; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Withholding Treatment | 2012 |
Discontinuation of statin therapy due to muscular side effects: a survey in real life.
Topics: Adult; Aged; Atorvastatin; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Motor Activity; Muscle Cramp; Muscle Weakness; Muscle, Skeletal; Musculoskeletal Diseases; Pain; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Surveys and Questionnaires; Treatment Outcome | 2013 |
Effects of statin treatments and polymorphisms in UGT1A1 and SLCO1B1 on serum bilirubin levels in Chinese patients with hypercholesterolaemia.
Topics: Adult; Aged; Analysis of Variance; Asian People; Bilirubin; Biomarkers; China; Female; Fluorobenzenes; Genetic Predisposition to Disease; Glucuronosyltransferase; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Liver-Specific Organic Anion Transporter 1; Male; Medication Adherence; Middle Aged; Organic Anion Transporters; Phenotype; Polymorphism, Genetic; Pyrimidines; Risk Assessment; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome; Up-Regulation | 2012 |
[Rosuvastatin-induced erythema multiforme].
Topics: Anti-Inflammatory Agents; Arthralgia; Drug Hypersensitivity; Drug Substitution; Emergencies; Erythema Multiforme; Female; Fluorobenzenes; Gemfibrozil; Humans; Hypercholesterolemia; Middle Aged; Prednisone; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2013 |
α1-Microglobulin/albumin ratio may improve interpretation of albuminuria in statin-treated patients.
Topics: Adolescent; Adult; Aged; Albuminuria; Alpha-Globulins; Case-Control Studies; Cholesterol; Creatinine; Cystatin C; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Kidney Tubules; Male; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2013 |
Are some statins more equal than others.
Topics: Anticholesteremic Agents; Controlled Clinical Trials as Topic; Dose-Response Relationship, Drug; Fluorobenzenes; Humans; Hypercholesterolemia; Pravastatin; Pyrimidines; Rosuvastatin Calcium; Simvastatin; Structure-Activity Relationship; Sulfonamides | 2002 |
Introduction: rosuvastatin--an efficacy assessment based on pooled trial data.
Topics: Atorvastatin; Clinical Trials as Topic; Coronary Artery Disease; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Meta-Analysis as Topic; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2003 |
Rosuvastatin--a new lipid-lowering drug.
Topics: Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertriglyceridemia; Hypolipidemic Agents; Pleurodynia, Epidemic; Pyrimidines; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Sulfonamides | 2003 |
Rosuvastatin calcium.
Topics: Cholesterol; Drug Approval; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2003 |
[New statin introduction. With more power against hypercholesterolemia].
Topics: Anticholesteremic Agents; Cholesterol, LDL; Clinical Trials, Phase III as Topic; Coronary Artery Disease; Dose-Response Relationship, Drug; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2002 |
A galaxy of acronyms and GALAXY as an acronym.
Topics: Fluorobenzenes; Humans; Hypercholesterolemia; Pyrimidines; Rosuvastatin Calcium; Sensitivity and Specificity; Sulfonamides; Terminology as Topic | 2003 |
Update on statins.
Topics: Atorvastatin; Coronary Disease; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2004 |
Rosuvastatin: new preparation. Opt for statins with evidence of efficacy on clinical outcome.
Topics: Anticholesteremic Agents; Clinical Trials as Topic; Double-Blind Method; Drug Interactions; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pravastatin; Pyrimidines; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2004 |
Economic evaluation of a compliance-enhancing intervention in patients with hypercholesterolemia: design and baseline results of the Open Label Primary Care Study: Rosuvastatin Based Compliance Initiatives To Achievements of LDL Goals (ORBITAL) study.
Topics: Aged; Anticholesteremic Agents; Cholesterol, LDL; Clinical Protocols; Cost of Illness; Female; Fluorobenzenes; Health Care Costs; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Patient Compliance; Pyrimidines; Randomized Controlled Trials as Topic; Research Design; Rosuvastatin Calcium; Sulfonamides | 2004 |
Rosuvastatin attenuates monocyte-endothelial cell interactions and vascular free radical production in hypercholesterolemic mice.
Topics: Animals; Aorta, Thoracic; Cell Communication; Cells, Cultured; Dose-Response Relationship, Drug; Endothelial Cells; Female; Fluorobenzenes; Free Radicals; Hypercholesterolemia; Mice; Mice, Inbred C57BL; Monocytes; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2005 |
Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Metabolic Syndrome; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome; Triglycerides | 2005 |
Rosuvastatin is cost-effective compared with atorvastatin in reaching cholesterol goals.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Cost-Benefit Analysis; Double-Blind Method; Europe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; North America; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Triglycerides | 2005 |
Decreasing LDL cholesterol and medication cost with every-other-day statin therapy.
Topics: Atorvastatin; Cholesterol, LDL; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Sulfonamides | 2005 |
Rosuvastatin: a safe and effective treatment for dyslipidaemia associated with non-alcoholic steatohepatitis (NASH).
Topics: Dyslipidemias; Fluorobenzenes; Hepatitis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrimidines; Rosuvastatin Calcium; Steatitis; Sulfonamides | 2006 |
Ezetimibe/simvastatin single tablet versus rosuvastatin in patients with hypercholesterolemia.
Topics: Anticholesteremic Agents; Azetidines; Drug Combinations; Ezetimibe, Simvastatin Drug Combination; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrimidines; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Tablets | 2006 |
Monday, Wednesday, and Friday dosing of rosuvastatin in patients previously intolerant to statin therapy.
Topics: Cholesterol, LDL; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorobenzenes; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2007 |
Diabetes and metabolic syndrome (MS).
Topics: Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Metabolic Syndrome; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2007 |
Comparative effectiveness of rosuvastatin versus other statin therapies in patients at increased risk of failure to achieve low-density lipoprotein goals.
Topics: Adult; Aged; Cohort Studies; Female; Fluorobenzenes; Guidelines as Topic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Lipoproteins, LDL; Male; Middle Aged; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Treatment Failure; Treatment Outcome | 2007 |
Effectiveness of rosuvastatin in low-density lipoprotein cholesterol lowering and National Cholesterol Education Program Adult Treatment Panel guideline III LDL-C goal attainment compared to other statins among diabetes mellitus patients: a retrospective
Topics: Adult; Aged; Cholesterol, LDL; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Medical Records Systems, Computerized; Middle Aged; Pyrimidines; Retrospective Studies; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2007 |
Effects of once weekly rosuvastatin among patients with a prior statin intolerance.
Topics: Adult; Aged; Drug Administration Schedule; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2007 |
Does hypercholesterolemia impair left ventricular function?
Topics: Case-Control Studies; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrimidines; Rosuvastatin Calcium; Selection Bias; Sulfonamides; Ventricular Dysfunction, Left | 2008 |
Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Cohort Studies; Coronary Disease; Databases, Factual; Fatty Acids, Monounsaturated; Female; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Male; Managed Care Programs; Odds Ratio; Pravastatin; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2007 |
Pharmacokinetics and pharmacodynamics of combined use of lopinavir/ritonavir and rosuvastatin in HIV-infected patients.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Drug Therapy, Combination; Fluorobenzenes; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lopinavir; Middle Aged; Pilot Projects; Pyrimidines; Pyrimidinones; Ritonavir; Rosuvastatin Calcium; Sulfonamides | 2007 |
Titration patterns with rosuvastatin as compared with other statins in clinical practice: a retrospective observational cohort study using an electronic medical record database.
Topics: Aged; Cholesterol, LDL; Cohort Studies; Databases, Factual; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Odds Ratio; Pyrimidines; Retrospective Studies; Risk Assessment; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2007 |
Skin blood flowmotion and microvascular reactivity investigation in hypercholesterolemic patients without clinically manifest arterial diseases.
Topics: Acetylcholine; Administration, Cutaneous; Aged; Blood Flow Velocity; Case-Control Studies; Endothelium, Vascular; Female; Fluorobenzenes; Fourier Analysis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Iontophoresis; Laser-Doppler Flowmetry; Male; Microcirculation; Middle Aged; Nitroprusside; Pyrimidines; Regional Blood Flow; Rosuvastatin Calcium; Skin; Sulfonamides; Treatment Outcome; Ultrasonography; Vasodilator Agents | 2009 |
Efficacy and safety of rosuvastatin in Taiwanese patients.
Topics: Adult; Aged; Aged, 80 and over; Cholesterol, HDL; Cholesterol, LDL; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrimidines; Retrospective Studies; Rosuvastatin Calcium; Sulfonamides; Triglycerides | 2008 |
[No reason to start treatment with statins in patients with moderate to severe heart failure].
Topics: C-Reactive Protein; Cholesterol, LDL; Drug Interactions; Fluorobenzenes; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrimidines; Risk Assessment; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2008 |
The comparative effectiveness of rosuvastatin vs. other statins in patients with an increased risk of failure to reach NCEP ATP III goal.
Topics: Cardiovascular Diseases; Cholesterol, LDL; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrimidines; Retrospective Studies; Risk Assessment; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2008 |
Statin cost-effectiveness comparisons using real-world effectiveness data: formulary implications.
Topics: Aged; Atorvastatin; Cholesterol, LDL; Cost-Benefit Analysis; Drugs, Generic; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2008 |
Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor.
Topics: Animals; Arteriosclerosis; Cholesterol, LDL; Clinical Trials as Topic; Drug Evaluation, Preclinical; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Molecular Structure; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2001 |
Rosuvastatin: do we need another statin?
Topics: Canada; Clinical Trials, Phase III as Topic; Drug Approval; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Technology Assessment, Biomedical; Treatment Outcome; United States; United States Food and Drug Administration | 2001 |